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Abstract 
 
Prostate cancer is the most frequently diagnosed cancer in men and poses a 
serious health threat to our aging society. Decades of research have 
improved detection and treatment options, and have led to a significant 
increase in life expectancy. However, the development of ultimately fatal 
castration-resistant prostate cancer still occurs frequently and treatment 
options are limited. The androgen receptor plays a crucial role in prostate 
cancer at all stages of the disease and thus constitutes the main drug target. 
Recent advances in molecular techniques, however, have uncovered other 
transcription factors that are commonly overexpressed and contribute to 
prostate cancer initiation and progression, and underpin expression profiles 
that classify the disease. Amongst these factors is c-Myc, which has been 
studied extensively in a variety of malignancies but its precise molecular 
function in prostate cancer remains largely elusive as of today.  
In this study, we sought to define the biological role of c-Myc in prostate 
cancer. Similar to other model systems, we found c-Myc to regulate a range 
of metabolic pathways, including purine biosynthesis. We focused on two 
enzymes within this pathway, PAICS and IMPDH2, and validated their 
overexpression in patient samples. Furthermore, we demonstrated the 
therapeutic potential of IMPDH2 inhibition by repurposing a clinically 
approved immunosuppressant. Notably, the biological effects of IMPDH2 
inhibition included a cellular stress response and the activation of tumour-
suppressive microRNAs. Next, we assessed the effects of c-Myc 
overexpression on androgen receptor chromatin occupancy and 
transcriptional output. We found that the androgen receptor and c-Myc 
share a substantial amount of target genes and networks, and that c-Myc 
overexpression antagonises androgen receptor activity. These findings are 
of utmost interest for the community since dysregulated androgen receptor 
activity is a major hallmark of prostate cancer. 

   3 
1. Introduction 
 
The following chapter will provide the reader with a comprehensive yet 
compact overview of the prostate, its anatomy and physiology as well as its 
diseases, predominantly prostate cancer. Befittingly, the reader will be 
introduced to current standards of diagnosis and treatment of the disease 
before receiving a thorough summary of its molecular principles. These 
principles include the current molecular model of prostate cancer and the 
most prevalent hallmarks. The introduction will be concluded with a 
detailed description of crucial transcriptional networks and their interplay in 
prostate cancer since the principal idea of functional interactions between 
transcription factors forms the theoretical basis of this thesis. Naturally, both 
the androgen receptor and c-Myc will receive special attention throughout 
this introductory part. 
 
1.1 Prostate anatomy and physiology 
 
The prostate gland is a walnut-shaped structure sitting just below the 
urinary bladder and in front of the rectum. It surrounds the proximal urethra 
as it exits the bladder and the ejaculatory duct coming from the seminal 
vesicles (Figure 1). Its purpose is to produce a milky-white fluid, which 
comprises roughly 30% of the ejaculate during sexual activity. This fluid 
contains high levels of zinc and citrate, which help to maintain sperm 
viability, presumably through calcium chelation, and provide an energy 
source to sustain mobility, respectively (1). High intraprostatic citrate levels 
are achieved through the accumulation of zinc via elevated levels of 
members of the zinc transporter family (hZIP) (Supplementary Paper IV) 
(2). Zinc in turn inhibits the citrate-oxidizing m-acotinase enzyme of the 
citric acid cycle, which leads to a build-up of citrate (3).  
Introduction 
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Anatomically, the prostate can be divided into three zones, (A) the 
peripheral zone (PZ) close to the rectum, (B) the central zone (CZ) 
surrounding the ejaculatory duct and (C) the transition zone (TZ), the 
innermost section surrounding the urethra (Figure 1). All three zones have 
different embryonic origins and differ vastly in their epithelial and stromal 
composition, and their susceptibility to prostatic diseases (Chapter 1.2) (4).  
 
 
Figure 1: Location of the prostate and anatomy 
 
The prostate gland sits underneath the urinary bladder and next to the seminal vesicles. It surrounds 
the urethra and the ejaculatory duct and produces a zinc-rich prostatic fluid, which comprises about 
30% of the ejaculatory fluid. Anatomically, it can be divided into three main zones (red). (1) Peripheral 
Zone (2) Central Zone (3) Transition Zone. Taken from (5) 
 
The size of the human prostate varies greatly with age and both its 
development and function are regulated by male sex hormones, androgens. 
The most prominent circulating androgen, testosterone, is primarily 
produced in the testes and exported to the bloodstream (6), where most of 
it is bound to albumin or Steroid Hormone Binding Globulin (SHBG) (6). 
Testosterone enters the prostate cells either through transporters or passive 
diffusion and is converted in the cytoplasm to the more potent 
dihydrotestosterone (DHT) through the activity of 5-α-reductase (5a-R) (7). 
DHT in turn binds the ligand-binding domain of the androgen receptor (AR), 
a ligand-activated transcription factor (TF). 
Introduction 
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Figure 2. Mechanism of transcriptional regulation by the androgen receptor  
 
Testosterone (T) in the extracellular matrix (ECM) is mainly bound by steroid hormone binding globulin 
and enters cells both passively through diffusion and with the help of transporters. Once in the 
cytoplasm, testosterone is converted to the more potent ligand dihydrotestosterone and binds to the 
AR, which releases the AR the chaperone HSP90. The AR dimerizes, gets phosphorylated and 
translocates into the nucleus. There it drives the expression of its target genes by recruitment of various 
transcriptional complexes, including histone acetyltransferases (HATs), lysine demethylases (KDMs), 
ATP-dependent chromatin modifiers (SWI/SNF) and the general transcription machinery. 
Androgen receptor 
The androgen receptor (AR) is an approximately 110kDa large nuclear 
receptor (NR), which is expressed in many cell types throughout the human 
body (Supplementary Paper IV)  (8). However, AR levels in the secretory 
luminal epithelial cells of the prostate are particularly high (9). In absence of 
a ligand, the AR is bound in the cytoplasm to heat-shock proteins, for 
example HSP90 (10) (Figure 2). Upon ligand binding, the AR is released 
Introduction 
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from the chaperone, homodimerises and is phosphorylated (11, 12). It then 
translocates into the nucleus, where it binds androgen-response elements 
in the genome and initiates transcription of its target genes. 
Mechanistically, the AR and other NRs modify chromatin structure through 
the recruitment of chromatin modifiers and remodelling enzymes, such as 
histone acetylases or demethylases (13-17), and ATP-dependent chromatin 
modifiers, such as the SWI/SNF complex, to promoter and enhancer regions 
(18-20) (Figure 2). Furthermore, the AR and other NRs also facilitate the 
recruitment of components of the general transcription machinery, such as 
RNA polymerase II, to promoter regions (21, 22).  
Importantly, the AR is essential for normal prostate development and 
function. For example, it controls the expression of hZIPs, which in turn 
increase intracellular zinc and concomitantly citrate levels (Chapter 1.1). 
However, it is also believed that the AR is the main initiator and driver of 
prostate cancer (PCa) and potentially other prostatic diseases (23). 
 
1.2 Prostatic diseases and prostate cancer 
 
The prostate is the origin of the two most common urological diseases of 
elderly men, PCa and benign prostatic hyperplasia (BPH). Other conditions 
that can occur in the prostate are prostatitis, or inflammation of the prostate 
gland, proliferative inflammatory atrophy (PIA) and prostatic intraepithelial 
neoplasia (PIN), both of which are considered precursors of PCa. Due to the 
prostate’s proximity to the reproductive and urinary systems, prostatic 
diseases often affect urination and sexual function.  
 
1.2.1 Prostatitis 
 
Prostatitis, infection or inflammation of the prostate gland, is the most 
common prostatic disease in men under 50 with prevalence between 5-9% 
Introduction 
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(24, 25). In fact, about 15-25% of all men will develop prostatitis at some 
point in their lives (26). Prostatitis is typically divided into four different 
subtypes, (A) acute, (B) chronic bacterial, (C) chronic nonbacterial and (D) 
asymptomatic (27). (A) and (B) are primarily caused by Escherichia coli and 
represent the best characterized but with about 10% of all cases also least 
common subtypes (28). About 90% of all symptomatic patients are 
diagnosed with chronic nonbacterial prostatitis (C), which thus far remains 
poorly understood. Potential triggers include viruses, urine reflux, dietary 
factors and physical trauma (29). The exact relationship between prostatitis 
and PCa risk has not yet been elucidated and remains a field of extensive 
research but it has been suggested that prostatitis may increase the risk for 
PCa and BPH (25, 27, 30, 31). This is further corroborated by the observation 
that bacterial prostatitis can exhibit molecular changes similar to PCa (32). 
 
1.2.2 Benign prostatic hyperplasia 
 
The inner part of the prostate (the TZ) often keeps growing with age, 
thereby exerting pressure on the urethra and causing discomfort and 
problems with urination. This condition is called benign prostatic 
hyperplasia (BPH). The TZ of the prostate makes up only 5% of the total 
volume but 100% of BPH cases emerge from this region (4). It is currently 
unclear whether BPH increases the risk to develop PCa and multiple 
publications support both sides of this highly controversial topic (33, 34).  
To treat BPH and relieve symptoms, excessive prostate tissue is often 
removed using transurethral resection of the prostate (TURP). Subsequent 
pathologic examination of the resected tissue occasionally reveals the 
presence of PCa. 
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1.2.3 Prostate cancer and precursors 
 
Proliferation of normal cells is carefully controlled by production and release 
of growth-promoting factors, which ensure tissue architecture, integrity and 
function (35). Cancer cells, however, have acquired the means to control 
their own destiny and proliferate independently.  
 
 
Figure 3. Current model of prostate cancer progression 
 
Prostate cancer (PCa) is thought to develop in a stepwise manner, starting with proliferative 
inflammatory atrophy (PIA) or prostatic intraepithelial neoplasia (PIN). It then progresses slowly to 
invasive PCa. Progression is characterised by atrophy, increased proliferation, enlarged nuclei and 
nucleoli and finally breach of the basement membrane and invasion of the stroma. It is currently 
thought that both luminal and basal cells can develop cancerous properties. 
Several hallmarks of cancer cells have been described and form the current 
basis of our understanding of the malignancy. These include the abilities to 
sustain proliferative signalling and to ignore growth suppressing effects, 
replicative immortality and the capacities to invade and metastasize into 
other tissues (35). Furthermore, cancer cells need to be able to evade cell 
death and stimulate angiogenesis to ensure supply with nutrients and 
oxygen. This classical list of cancer hallmarks has recently been expanded to 
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give justice to novel insights gained in recent years (36). Thus, the latest 
model suggests that cancer cells also require the capacity to deregulate 
cellular metabolism and to avoid detection or destruction by the host’s 
immune system. In addition, genomic instability and mutations as well as 
tumour-promoting inflammation are now seen as two typical characteristics 
of human tumours. Initially, PCa is a hormone-dependent cancer driven by 
androgens and the activity of the AR. It is often indolent, i.e. asymptomatic 
and barely growing but it can also be aggressive and fast growing. It is 
thought to develop in a step-wise manner, starting with proliferative 
inflammatory atrophy (PIA) or prostatic intraepithelial neoplasia (PIN) and 
subsequent slow progression to invasive adenocarcinoma (Figure 3).  
Proliferative inflammatory atrophy 
 
PIA is closely associated with chronic inflammation and describes a 
frequently observed lesion in prostate biopsies characterized by chronic 
inflammatory cell infiltrates, such as mast cells and macrophages, and 
atrophic glandular structures, mainly in the PZ of the prostate (37, 38) 
(Figure 3). The affected epithelial luminal cells exhibit enlarged nuclei, 
increased proliferation and a reduced apoptotic rate (39). This hypothesis is 
further corroborated by the observation that invading immune cells have 
been shown to stimulate the formation of cancer in various animal models, 
albeit not PCa. This is presumably mediated by secreted cytokines, such as 
tumour-necrosis factor alpha (TNF-α) (38, 40, 41). Due to its predominant 
localization in the PZ, PIA has been hypothesized to be a precursor lesion of 
prostatic intraepithelial neoplasia (PIN) or PCa (37). 
Prostatic intraepithelial neoplasia  
 
PIN is a precancerous lesion in which some luminal cells of the prostate 
epithelium start to look and behave abnormally. They exhibit enlarged 
nuclei and nucleoli, and increased abnormal proliferation (42, 43). 
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Importantly though, these changes only affect luminal cells; the basement 
membrane, which forms the lining of the epithelium, remains intact (Figure 
3). 
PIN itself is usually asymptomatic but considered a precursor of PCa. It is 
often discovered in biopsies taken when PCa is suspected, and it harbours 
many of the genetic alterations present in PCa (Chapter 1.5.1). However, it 
does not yet represent an invasive carcinoma. Historically, PIN was 
subdivided into three groups, I, II and III, which were classified as low grade 
(I) and high grade (II and III) PIN. Because low grade PIN does not have any 
prognostic value, PIN is nowadays often used as a synonym for high grade 
PIN (HGPIN). Clinically, various studies have shown that patients with HGPIN 
have an increased risk of a subsequent PCa diagnosis although this area 
remains highly controversial since subsequent studies reported otherwise 
(44-47). Just as PCa, PIN is most likely to occur in the PZ of the prostate. 
Prostate cancer 
 
The diagnosis changes from PIN to PCa once the uncontrolled proliferation 
of epithelial cells penetrates the basement membrane and cells invade the 
stroma (Figure 3) (48). Eventually, the tumour might grow large enough to 
invade surrounding tissues and organs, such as the seminal vesicles, the 
lymph nodes or the rectum. It might also spread to distant organs via the 
bloodstream and form metastases. The most common metastatic sites in 
PCa are bone (90%), lungs (46%) and liver (25%) (49). 
Approximately 70% of all prostate cancers originate in the PZ and about 
25% in the TZ. Interestingly, cancers of the CZ are rather uncommon and 
comprise only about 5% of all PCa (4). In contrast to many other epithelial 
cancers, such as breast cancer, there are hardly any distinguishable 
histopathological subtypes in PCa. The vast majority (>90%) of PCas are 
adenocarcinomas, i.e. cancers of the glandular epithelial cells. Other rare 
cancer types include ductal adenocarcinomas (originate in the prostatic 
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duct), squamous cell carcinomas (originate in the flat cells covering the 
prostate gland), sarcomas (originates in prostatic muscle cells) or small cell 
carcinomas (a type of neuroendocrine tumour). The exact cell type of origin 
of PCa in the glandular epithelium still remains controversial and there is 
evidence that both basal and luminal cells can give rise to PCa (Figure 3) 
(50-53). It is thought that luminal-cell-containing tumours can evolve from 
basal-cell-induced cancers, potentially explaining the lack of basal cell 
markers in patient tumours (54).  
 
1.3 Epidemiology of prostate cancer 
 
PCa is the most common cancer in men and the second most common 
cause of cancer-related death in men (55). According to the American 
Cancer Society, more than 240,000 men were diagnosed with PCa in 2011 in 
the US and more than 33,000 men died of it (55). Worldwide, the numbers 
for new diagnoses and deaths in 2012 were 1.11 million and 300,000, 
respectively (56). Currently, the lifetime risk, i.e. the risk of a newborn child 
to develop PCa at some point in their life is approximately 14% (1 in 7) (56). 
Norway has one of the highest incidences of PCa worldwide (129.7 age-
standardised rate per 100,000 people) with 4,919 new diagnoses and 1,006 
deaths in 2012 (57, 58).  Strikingly, Northern European countries, such as 
Norway, Sweden or Finland, appear to have particularly high PCa incidence 
and mortality rates (59). In general, PCa is a disease of the elderly in the 
developed world; the average age at diagnosis is 66 and about 60% of men 
diagnosed are 65 or older (56). However, about 10% of all PCa cases are 
diagnosed in men under the age of 55 (60). These early onset cancers are 
generally more aggressive and have a higher mortality rate than men 
diagnosed at older age, except those over the age of 80 (60). It has been 
postulated that these early onset cases have a strong genetic component 
and these men could benefit from risk loci screening (60). 
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Risk factors 
 
Several endogenous and exogenous risk factors are suspected to contribute 
to the development and/or progression of PCa (Table 1). When it comes to 
endogenous factors, age is by far the most significant risk factor for PCa. The 
vast majority of patients diagnosed with PCa are in their sixties with an 
average age of 66 at diagnosis (56). Another strong link exists between race 
and PCa: in the UK, black men are, depending on age group, 1.1 to 3.4 more 
likely than white men to develop PCa (61). In the US, both their risk to 
develop and their risk to die from PCa are significantly higher in comparison 
to white men (62). Although other factors, such as socio-economic status or 
demographic characteristics, certainly play a major role, they are not 
sufficient to explain this disparity in its entirety (63). Furthermore, obesity 
and high levels of Insulin-like growth factor 1 (IGF-1) have been shown to 
increase PCa risk and risk of death from PCa (64-67). Another risk factor is 
family history; a man whose father and/or brother has or had PCa is 
approximately 2-3 times more likely to develop PCa himself (68, 69). The risk 
of early onset PCa is associated with family history and these patients are 
also more likely to carry a larger number of genetic variants than older men 
who develop PCa (60, 70).  
Various genome-wide association studies (GWAS) have linked a host of 
genomic loci to PCa risk (71-74). The underlying biological mechanisms, 
however, remain to be elucidated for most of them, as they predominantly 
lie in gene-free regions of the genome. A notable exception is the recent 
discovery of a single-nucleotide polymorphism (SNP) in a risk-associated 
allele on chromosome 6q22, which the authors could link to an in increase 
in HOXB13 binding to the enhancer region of RFX6 (75, 76). Strikingly, a 
germ line mutation in the HOXB13 gene itself has been reported to increase 
the risk for PCa and the prevalence of this mutation was highest in Sweden 
and Finland (77, 78). Germ line mutations in the BRCA2 gene, which 
dramatically escalate the risk of breast and ovarian cancer have also been 
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shown to increase the risk for PCa approximately 7-fold (79). In total, about 
5-9% of all PCas are estimated to be familial, i.e. linked to genes and family 
history (80). 
 
Table 1. Summary of prostate cancer risk factors 
 
Risk factor(s) Prostate cancer risk References 
   
Endogenous factors   
Age Increased with age (56) 
Race Increased in black men (61, 63) 
Family history of PCa Increased (68, 69) 
Obesity/High IFG-1 levels Increased (64-67) 
   
Genetic factors   
BRCA2 Early-onset risk increased when mutated (79) 
HOXB13 Increased when mutated (77, 78) 
various SNPs Both (71-76) 
   
Exogenous factors   
Calcium, folate, cadmium Increased (limited evidence) (81-85) 
Arsenic, pesticides Increased (limited evidence) (86-88) 
Lycopenes, selenium Decreased (limited evidence) (89-92) 
 
Neither the International Agency for Research on Cancer (IARC), nor the 
World Cancer Research Fund/American Institute for Cancer Research 
(WCRF/AICR) have thus far classified any exogenous factor as having 
‘sufficient’ or ‘convincing’ evidence to promote PCa risk (93, 94). Several 
potential risk factors, however, are considered to have ‘limited’ or ‘probable’ 
evidence. These include but are not limited to dietary components (calcium, 
folate, cadmium), occupational exposures (arsenic, pesticides), testosterone 
supplements and ionizing radiation. On the other hand, factors that might 
decrease the risk for PCa but lack ‘sufficient’ or ‘convincing’ evidence 
include physical activity and dietary components (lycopenes, selenium) (93, 
94). 
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1.4 Prostate cancer diagnosis and treatment 
 
In more than 65% of newly diagnosed cases, PCa is asymptomatic (95). 
Some early stage patients, however, experience varying symptoms, 
including lower back pain, difficulty urinating or bloody urine (hematuria). 
In later stages, PCa often causes bone pain in the vertebrae or pelvis due to 
metastatic spread. When PCa is suspected, only a biopsy can confirm or 
refute the diagnosis but often less invasive methods are used to gather 
additional information, including Prostate-specific antigen (PSA) testing, 
digital rectal exam (DRE) or prostate imaging. Most patients screened for 
PCa are diagnosed with localised disease and only few patients present 
metastatic disease upon initial diagnosis (96). 
 
1.4.1 Diagnosis parameters 
 
Clinical PCa staging is usually conducted using the TNM (Tumour-Node-
Metastasis) system devised by the American Joint Committee on Cancer  
(AJCC) and the International Union Against Cancer (UICC) in 1992 (97). The 
system is constantly being revised and the most current version originates 
from 2010 (98). If radical prostatectomy is performed during treatment, the 
initial clinical stage might be corrected after a thorough examination of the 
removed tissue. This so-called pathologic staging is likely to be more 
accurate than the initial clinical assessment, as it is based on first-hand 
impressions of isolated tissue rather than biopsy samples. Both staging 
procedures use the same categories but T1-stage is only used in clinical 
staging. 
In addition to the TNM system, which is also used in other cancers, two 
prostate-specific criteria, PSA levels and Gleason grading, determine the 
clinical stage grouping of PCa. These five parameters will be described in 
more detailed in the following. 
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Tumour stage 
 
Tumour stage or T-stage is used to describe the tumour’s extend. The 
following main categories and subcategories are currently being used 
(Table 2) (97). 
 
Table 2: Tumour stage categories 
 
TX  Tumour stage could not be assessed 
T0  No evidence of primary tumour 
T1  Tumour cannot be felt by DRE or detected by ultrasound 
 T1a Cancer was accidentally found during a TURP procedure and represented less than 
5% of the resected tissue 
 T1b Cancer was accidentally found during a TURP procedure and represented more than 
5% of the resected tissue 
 T1c Cancer was found by needle biopsy, which was performed due to increased PSA 
levels 
T2  Tumour is confined to the prostate 
 T2a Tumour involves a maximum of 50% of a single lobe 
 T2b Tumour involves more than 50% of a single lobe but not the other 
 T2c Tumour involves both lobes 
T3  Tumour extends through the prostate capsule 
 T3a Tumour extends outside the prostate but does not involve the seminal vesicles 
 T3b Tumour extends to the seminal vesicles 
T4   Tumour is fixed or invades adjacent structures, such as external sphincter, rectum, 
bladder, levator muscles or pelvic wall 
 
 
Node stage 
 
Node stage or N-stage is used to describe whether the tumour has spread to 
nearby lymph nodes. The following categories are currently being used 
(Table 3) (97). 
 
Table 3: Node stage categories 
 
NX Nearby lymph nodes were not assessed 
N0 Tumour has not spread to nearby lymph nodes 
N1 Tumour has spread to nearby lymph nodes 
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Metastasis stage 
 
Metastasis stage or M-stage is used to describe the tumour’s extend to 
distant tissues and organs. The following main categories and subcategories 
are currently being used (Table 4) (97). 
 
Table 4: Metastasis stage categories 
 
M0  No distant metastases could be detected 
M1  Distant metastases are present 
 M1a Metastases in non-regional lymph nodes 
 M1b Bone metastases 
 M1c Other metastases with or without bone involvement 
 
Prostate-specific antigen 
 
Prostate-specific antigen (PSA) is a member of the kallikrein subgroup of 
serine proteases and the AR tightly controls its expression. It is almost 
exclusively expressed in secretory epithelial cells in the PZ of the prostate, 
where it is rendered inactive by high intracellular zinc concentrations (99). 
Upon ejaculation, PSA in the prostatic fluid is mixed with sperm and 
activated in the slightly acidic vaginal environment, where lower zinc 
concentrations are prevalent. Once active, PSA digests the main component 
of the sperm-entrapping coagulate, the seminal plasma motility inhibitor 
precursor/semenogelin I (SPMIP/SgI), which leads to the release of motile 
sperm cells (100, 101).  
In patients with a healthy, normal prostate, PSA is confined to prostate cells 
and sperm, and thus blood levels are low. Its levels, however, positively 
correlate with the patient’s age and size of his prostate (102). Furthermore, 
race-specific differences have been reported (103). Therefore, normal age- 
and race-specific reference values range from 0 to approximately 7ng per ml 
of blood. Prostatic diseases, including BPH and PCa, often disrupt the 
integrity of the basal cell layer and basement membrane (Figure 4), which 
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leads to a leakage of PSA into the bloodstream (104). Consequently, 
assessing blood levels of PSA in combination with DRE was initially thought 
to be of value as a biomarker for the early detection of asymptomatic PCa.  
However, not every PCa patient has high PSA blood levels and conversely 
not every patient with a high PSA level has PCa for PSA levels are also 
elevated in other prostatic diseases (105). Furthermore, PSA blood levels are 
also influenced by other factors, such as recent DRE or obesity (106-108). 
Hence, in recent years routine PSA screening has become less popular since 
benefits for patients remain questionable, and overdiagnosis and 
overtreatment occur frequently (109). PSA, however, is still routinely used to 
measure progression in PCa patients after initial treatment as rising PSA 
values indicate biochemical recurrence (BCR) and potentially treatment 
failure (Chapter 1.4.5). 
 
 
 
Figure 4. Original Gleason scoring system and recent modifications  
 
 (Left) The original scoring devised by Donal Gleason in 1966. (Centre) Modifications introduced after 
the 2005 meeting of the International Society of Urological Pathology (ISUP) (Right) Recent 
modifications proposed by  Jonathan I. Epstein and colleagues in 2010. Modified from (110) 
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Gleason grading 
 
Donald Gleason first described the Gleason grading system in 1966. It 
underwent major revisions in 2005 and 2010 (111, 112), but still remains a 
valuable tool for PCa diagnosis and prognosis (113) (Figure 4). 
Basically, a pathologist examines prostate specimen derived from a biopsy 
or radical prostatectomy under a microscope and assesses the architectural 
patterns of the gland. The pathologist then assigns a score from 1 to 5 to the 
two most prevalent patterns in the specimen, based on the level of cell 
differentiation and the presence of cribriform structures (Figure 4).  
Although the grading system ranges from 1 to 5, pathologists practically do 
not use 1 and 2. Both assigned scores are combined and result in a total 
Gleason score ranging from 6 to 10. In principal, the higher the combined 
Gleason score, the worse the prognosis for the patient.  
 
1.4.2 Staging  
 
Based on the five parameters PSA level, Gleason score and TNM stage, 
patients are sorted into one of currently five stages (Table 5), which help 
doctors and patients to make appropriate treatment decisions. 
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Table 5: Prostate cancer stages defined by TNM, Gleason and PSA 
 
Stage  T N M Gleason PSA 
       
I  T1a-c N0 M0 ≤6 <10 
  T2a N0 M0 ≤6 <10 
  T1-2a N0 M0 X X 
II A T1a-c N0 M0 7 <20 
  T1a-c N0 M0 ≤6 ≥10&<20 
  T2a N0 M0 7 <20 
 B T2b N0 M0 ≤7 <20 
  T2b N0 M0 X X 
  T2c N0 M0 Any Any 
  T1-2 N0 M0 ≥8 Any 
  T1-2 N0 M0 Any ≥20 
III  T3 N0 M0 Any Any 
IV  T4 N0 M0 Any Any 
  Any N1 M0 Any Any 
  Any Any M1 Any Any 
 
1.4.3 Treatment 
 
First and foremost, the patient and his doctor have to decide whether a 
treatment is advisable at all. Many prostate tumours are asymptomatic and 
slow growing or even indolent. Furthermore, the advanced age or 
deteriorated health of many patients might make treatment undesirable or 
impossible. Hence, a careful assessment of the patient’s individual situation 
is necessary to identify indolent or aggressive cancers to avoid 
overtreatment and unnecessary suffering. To aid doctors and patients in 
their decision, several risk assessment methods have been devised over the 
years to predict PCa specific mortality on the basis of pre-treatment risk. 
Two major approaches are nowadays widely used, the D’Amico Risk 
Stratification (114), and the University of California, San Francisco Cancer of 
the Prostate Risk Assessment (UCSF-CAPRA) score (115). Both methods use a 
variety of clinical parameters, including PSA, Gleason score and tumour 
stage. In addition, the UCSF-CAPRA score includes age and ‘% of biopsy 
cores positive’ (115). 
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Once PCa has been diagnosed and staged, several principal treatment 
options are available (based on the current recommendations by the 
American Cancer Society) (116).  
Stage I cancers are often very small and therefore rarely require treatment. 
Thus, active surveillance and regular follow-up to monitor the tumour’s 
development is the commonly chosen approach in these cases. Sometimes, 
however, radical prostatectomy or radiation therapy might be suitable 
options. 
Stage II cancers are larger than stage I but are still confined to the prostate. 
They are, however, more likely to spread to lymph nodes or other organs. As 
with stage I cancers, active surveillance and, where appropriate, radical 
prostatectomy or radiation therapy are commonly recommended treatment 
strategies. 
Stage III cancers have expanded beyond the prostate and thus radical 
prostatectomy (often with removal of the surrounding lymph nodes), 
radiation therapy and hormonal therapy, such as androgen-deprivation 
therapy (ADT), are common approaches. ADT aims at disrupting the  
AR, a critical TF in PCa (Chapter 1.1.1). Stage III cancers have a higher 
probability of relapsing after treatment than lower stage cancers. 
Treatment options for stage IV cancers include the abovementioned 
therapy options, classic chemotherapy, experimental clinical trials and, if all 
other options fail, palliative care. 
 
1.4.4 Prognosis 
 
Prognosis of PCa is generally favourable due to the slow growth of most 
early stage prostate tumours and the advanced age of most patients at 
diagnosis. Furthermore, due to extensive PSA testing, PCa is usually 
detected early and most patients screened for PCa are diagnosed with 
localised disease (96). Thus, the relative cancer-specific 5- and 10-year 
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survival rates are higher than 90% when all PCa stages are included (117, 
118). 
Usually, however, the five different stages are subgrouped into three 
different groups, each having different prognoses. Group 1 or localised 
disease includes stages I and II (A and B), group 2 describes locally advanced 
disease (Stage III and non-metastatic stage IV cancers) and group 3 
describes metastatic PCa (stage IV with metastases) (117). 
The 5-year survival rate for patients presented with low-grade cancers 
(group 1) at diagnosis is about 98%. For advanced localised cancers (group 
2), this drops to approximately 70% and patients with metastatic disease 
(group 3) have a 5-year survival rate of approximately 30% (118). However, 
these values are dramatically influenced by time of diagnosis, individual 
background and chosen treatment options. 
 
1.4.5 Castration-resistant prostate cancer 
 
Regardless of what kind of treatment is chosen by the patient, PSA blood 
levels usually drop significantly post-treatment, as the tumour is surgically 
removed (radical prostatectomy) or goes into remission (radiotherapy/ADT). 
Subsequently, patients receive regular follow-up and PSA levels are 
routinely measured to detect potential relapse (Figure 5). An increase in 
post-treatment PSA levels indicates BCR but currently no clear consensus 
definition of a clinically relevant increase exists. Depending on initial 
tumour stage and treatment, approximately 15-35% of PCa patients will 
develop BCR within ten years (119-121). The standard of care for these 
patients is ADT, albeit the appropriate timing (early/late) for treatment 
remains controversial (122-125).  
Initially, most patients with BCR respond to ADT to varying extent but 
ultimately the cancer becomes resistant, a stage called castration-resistant 
prostate cancer (CRPC) or metastatic CRPC (mCRPC). Approximately 30% of 
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patients with BCR will develop mCRPC within 8 years of BCR (119). Over 90% 
of CRPC patients display bone metastases but liver, lung and adrenal gland 
metastases are also observed (49, 126, 127). CRPC is a fatal disease and the 
average overall survival is less than 1.5 years but varies significantly with 
different metastatic sites (128). Although a variety of treatments for CRPC 
have been approved in recent years and treatments might be beneficial in 
individual cases, no curative treatment for CRPC is currently available (128). 
This underlines the importance of finding new treatments for CRPC. 
 
Figure 5: The development of castration resistant prostate cancer  
 
Successful treatment of localised prostate cancer, usually by radical prostatectomy or radiation therapy 
leads to remission of the tumour and a drop in Prostate-Specific-Antigen (PSA) levels. Afterwards, 
patients receive regular follow-up and PSA measurements to assess treatment efficacy and potential 
relapse. A rise in post-treatment PSA, which occurs in about 15-35% of patients, is called BCR. Within 8 
years of BCR, approximately 30% of patients will develop metastatic castration resistant prostate 
cancer, which has an average survival of less than 1.5 years. 
The following treatment options are taken from the guidelines for the 
treatment of CRPC published by the European and American Urological 
Associations (EAU and AUA, respectively) (127, 129). Current first- and 
second-line treatments of CRPC include the autologous vaccine Sipuleucel-
T (not approved in Europe), the anti-mitotic chemotherapeutics Docetaxel 
and Cabazitaxel, the immunosuppressant Prednisone, the androgen-
biosynthesis-inhibitor Abiraterone acetate and the anti-androgen 
Enzalutamide (MDV3100) (127, 129).  In addition, treatments targeting the 
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highly prevalent bone metastases are also implemented. These include the 
monoclonal antibody Denosumab, the bisphosphonate Zoledronate and 
the radiopharmaceutical radium-223 (127, 129-131). However, survival 
remains disappointing despite large therapeutic randomised controlled 
trials, such as the Systemic Therapy in Advancing or Metastatic Prostate 
Cancer (STAMPEDE) trial, which included a large variety of treatment 
approaches for mCRPC (132, 133). 
 
1.5 Molecular biology of prostate cancer 
 
On a molecular level, the exact causes and mechanisms of progression of 
PCa and CRPC remain largely elusive as of today. Its hormone-dependency, 
however, has been known for decades and has thus been at the centre of 
extensive research. Historically, Charles Huggins was the first to describe the 
benefits of castration and ADT for metastatic PCa in the 1940s (134, 135). 
This ground-breaking discovery, for which he was later awarded the Nobel 
Prize Physiology or Medicine in 1966, marked a new era of PCa treatment 
and research. In the late 1960s, the AR was discovered and briefly afterwards 
the first chemical anti-androgen that prevented the binding of DHT to the 
AR, Cyproterone acetate, hit the market (136-138). Ever since, PCa research 
has been focused on the AR and improving ADT, and several new anti-
androgens have been developed. However, while treatment of PCa and 
concomitantly life expectancy have improved significantly since the early 
days, CRPC still remains a poorly understood and fatal disease. 
In recent years, advances in molecular techniques have led to the discovery 
of a whole array of thus far unknown molecular alterations in PCa and CRPC, 
opening up new diagnostic and therapeutic avenues. Through extensive 
research, many of these alterations have been attributed to various 
precursors and stages of PCa (Figure 6), and the current status of 
knowledge will be summarised in the following chapter. 
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1.5.1 Molecular model 
 
The current molecular model of PCa proposes that early insults, such as 
aging, infection and hereditary factors, afflict parts of the prostate, causing 
DNA damage, oxidative stress, telomere shortening, cell injury and death, 
and potentially invasion of immune cells (PIA) (38, 139). It has been 
proposed that this ‘field effect’ affects a certain proportion of the prostate 
and some epithelial cells respond to these insults with atrophy, increased 
proliferation (downregulation of PTEN, NKX3.1 and p27) and stress-response 
(upregulation of GSTP1 or PTGS1). In a subset of these cells, GSTP1 is 
repressed through promoter methylation. GSTP1 repression and NKX3.1 
downregulation as well as other factors are thought to affect the efficacy of 
DNA damage repair (specifically double strand break repair) and thus 
increase the chance of illegitimate recombination and chromosomal 
rearrangements (140), which are frequently observed in PIN and PCa. 
Importantly, double-strand breaks are normal events occurring in AR-
mediated transcription (141, 142). The emerging chromosomal losses, gains 
and rearrangements include PTEN and NKX3.1 LOH, 8q24 amplification and 
multiple gene fusions (e.g. TMPRSS2-ERG) (Figure 6). Interestingly, the 8q24 
locus contains the TF MYC, which has been shown to promote genomic 
instability and this could further increase the frequency of chromosomal 
rearrangements (143).  
These rearrangements induce changes in expression patterns and activity 
spectra of TFs and chromatin remodelers. Thus, the AR is exposed to a range 
of novel or altered interactors and cofactors, which are thought to influence 
its transcriptome and interactome (144) (Figure 7). This results in the 
transcription of different genes, thus changing the cellular composition of 
proteins, altering the cell’s identity and inducing transformation (144). 
Furthermore, loss of cell cycle control (p53 mutations and RB1 loss) occurs 
frequently in PCa, leading to increased proliferation and tumour growth. 
Late stage cancer and CPRC are dominated by AR-related mutations and 
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amplifications, which increase the sensitivity of the AR, render it sensitive to 
other ligands, produce ligand-independent splice variants of the AR or 
provide cancer cells with the ability to produce DHT in an autocrine manner 
to sustain cell proliferation (145-150). 
 
Figure 6. Molecular model of prostate cancer and its precursors 
 
Proliferative inflammatory atrophy (PIA) is characterized by inflammatory stresses in epithelial cells, 
presumably caused by invading immune cells. In combination with other factors, such as age, diet or 
genetic predisposition, this leads to atrophy and increased proliferation through the downregulation of 
p27, PTEN and NKX3.1 and methylation of the GSTP1 promoter. These alterations are thought to impair 
a host of cellular processes, amongst others DNA damage repair. Inaccurate double strand break repair 
leads to illegitimate recombination and genomic instability. Thus, chromosome and gene amplification 
(e.g. 8q24/MYC), loss of heterozygocity (e.g. PTEN and NKX3.1) and gene fusions (e.g. TMPRSS2-ERG) 
occur frequently and are thought to drive the neoplastic phenotype, resulting in prostatic 
intraepithelial neoplasia (PIN) and prostate cancer (PCa). In PCa, loss of cell cycle control (p53, Rb1) 
further drives proliferation. In later stages and CRPC, mutations and amplifications of the androgen 
receptor (AR), which are thought to maintain the transcriptional activity of the transcription factor (TF), 
are highly prevalent. 
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Notably and consistent with the ‘field effect’ hypothesis, it has been shown 
that non-cancerous cells of the prostate often harbour a subset of genomic 
alterations of their cancerous counterparts (151). Furthermore, several 
studies have shown that 60-90% of localised PCas are multifocal (152-155), 
i.e. two or more tumours are present in a single prostate. These tumours are 
spatially separate and usually clonally distinct, i.e. have different Gleason 
scores, different stages and harbour different molecular and genetic 
alterations (156).  
 
 
Figure 7. Transcriptional control by the AR in normal and transformed prostate cells 
 
In normal prostate cells, the AR drives a transcriptional program resulting in differentiation and the 
accumulation of zinc and citrate. It drives expression through interaction with and recruitment of 
chromatin remodelling complexes (SWI/SNF), lysine demethylases (KDMs), histone acetyltransferases 
(HATs) and RNA polymerase II in combination with general TFs. In transformed cells, however, the AR is 
exposed to and interacts with a different range of TFs and co-regulators, leading to altered 
transcriptional output. These factors include but are not limited to ETS, homeobox and forkhead 
factors, and altered PI3K signalling. The altered transcriptional output results in abnormal proliferation, 
increased invasion and elevated androgen synthesis.  The impact of MYC on AR signalling in prostate 
cancer has not been studied extensively yet. 
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Two principal theories about the origins of multifocality exist, (1) 
multiclonality of the initial disease, i.e. the tumours were different to begin 
with or (2) clonal evolution from the initial disease, i.e. the previously 
identical tumours evolved in different directions (157). This area of research 
remains controversial but undoubtedly, multifocality and heterogeneity are 
highly prevalent characteristics of PCa.  
In contrast to the local tumour, however, PCa metastases have been shown 
to be of monoclonal origin and maintain the unique genetic signature of 
the parental cancer cell (158, 159). Surprisingly, it was recently shown that 
the lethal cell clone of a deceased patient did not originate from the large, 
high-grade primary tumour or a lymph node metastasis, but rather 
unexpectedly from a smaller, low-grade cancer focus in the primary tumour 
(160). This interesting case illustrates the challenges multifocality and 
heterogeneity impose on diagnosis and treatment of PCa. 
 
1.5.2 Clinically relevant molecular hallmarks 
 
Despite being a highly heterogeneous and multifocal disease, a host of 
molecular hallmarks are particularly prevalent in PCa and its precursors PIA 
and PIN. As mentioned in Chapter 1.5.1, chromosome aberrations are 
thought to promote the development of PCa and thus many of the 
frequently observed alterations fall into this category (Table 6). 
Furthermore, activating and suppressing mutations are also regularly 
observed. Mechanistically, the most common changes can be divided into 
five categories, (1) Signalling pathways, (2) Cell cycle control, (3) 
Transcription factors, (4) Transcriptional cofactors and chromatin regulators 
and (5) Others. The most common alterations are summarized in the 
following table (Table 6) (161, 162). Interestingly and in contrast to other 
cancers, such as colorectal or kidney cancer (163), PCa appears to be largely 
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devoid of highly recurrent somatic mutations with the notable exception of 
p53 mutations in mCRPC (164). 
 
Table 6: Overview of clinically relevant molecular hallmarks of PCa 
 
Gene/protein Alteration(s) Earliest 
stage 
References 
I. Signalling pathways    
PTEN downregulation, LOH (10q23) PIA, PCa (164-169) 
PIK3CA amplification, mutation PIN?, PCa (164, 165, 170, 
171) 
MAPK/ERK1/2 early decrease, late increase PIN, CRPC (172-174) 
    
II. Cell cycle control    
RB1/BRCA2 LOH (13q) PCa (175-178) 
CDKN1B (p27) downregulation, loss (12p12) PIA (37, 179) 
    
III. Transcription factors    
TP53 mutation, LOH (17p) PCa (165-168, 180-
182) 
MYC amplification (8q24), overexpression PIN (164, 183-186) 
AR amplification (Xq), overexpression, 
mutations 
CRPC (147, 148, 164, 
168, 187, 188) 
ERG/ETV1/ETV5 gene fusion (TMPRSS2, 21q etc) PIN/PCa (164, 189-192) 
NKX3.1 downregulation, LOH (8p) PIA/PIN (193-195) 
    
IV. Cofactors and chromatin 
regulators  
   
NCOA2 mutation, amplification (8q) PCa (161, 166, 167, 
181) 
EP300 mutation PCa (161, 166, 167, 
181) 
NCOR2 mutation PCa (161, 166, 167, 
181) 
FOXA1/O1/O3/P1 mutation, loss (3p, 6q, 13q) PCa (164-167) 
MLL2/3 mutation PCa (161, 166, 167, 
181) 
CHD1 mutation, loss (5q21) PCa (161, 166, 167, 
196, 197) 
EZH2 amplification (7q), overexpression CRPC (164, 198, 199) 
    
V. Others    
GSTP1 promoter methylation (11q13) PIA/PIN (200) 
SPOP mutation PCa (156, 164, 165, 
181, 197) 
 
Undoubtedly, TFs, transcriptional cofactors and chromatin modifiers are 
highly abundant in this list. Thus, understanding transcriptional regulation 
and the interplay between these factors are of utmost importance to 
improve PCa detection, classification and treatment.  
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1.5.3 Transcriptional networks and their interplay 
 
PCa is a hormone-dependent cancer driven by androgens and the AR. Thus, 
most therapeutic interventions aim at perturbing AR activity and lowering 
its transcriptional output. Recent advances in molecular techniques, 
however, have uncovered a multitude of cofactors and interactors, which 
influence AR-mediated transcriptional control in PCa and CRPC, and also 
interact with each other (Figure 7 and Figure 8).  
 
Figure 8. Interplay of transcription factors, chromatin modifiers and signalling pathways 
Various publications have begun to uncover a sophisticated network of TFs, chromatin modifiers and 
signalling pathways in PCa. Examples of reported interactions between commonly altered components 
of the cellular machinery are highlighted with single-headed arrows (symbolizes activation), blunt 
arrows (repression), double-headed arrows (cooperation) or double-headed blunt arrows (reciprocal 
feedback). See text for details and references. 
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Understanding the impact these interactors have on AR activity and 
transcriptional output will be crucial for a deeper understanding of the 
disease and will ultimately produce better treatment options. To this end, 
researchers have made extensive use of chromatin immunoprecipitation 
coupled with high-throughput sequencing (ChIP-seq) and gene expression 
analysis using expression arrays or more recently high-throughput RNA-
sequencing (RNA-seq). These techniques have proven valuable in defining 
binding properties and activity spectra of the AR and other TFs, and 
chromatin regulators. Befittingly, we make use of these techniques in Paper 
III of this thesis. 
Androgen receptor signalling and its modulation 
 
The AR is a ligand-activated TF essential for normal prostate development 
and function (Chapter 1.1.1) but it is also the main initiator and driver of 
PCa. Extensive unbiased approaches have defined the transcriptional 
network of the AR in various PCa cell lines and more recently clinical 
samples (201-203). Through these experiments, it has been shown that the 
AR directly controls metabolism and cell cycle genes to fuel anabolic 
metabolism resulting in increased proliferation (202).  
It has been postulated that excessive ADT may lead to CRPC, which is 
ultimately fatal. Strikingly, most CRPCs still express a functional AR network, 
which is immune to current AR-perturbing therapies. The activity of the AR 
is presumably maintained through a range of mutations, including point 
mutations and gene amplifications (146, 147, 187). Furthermore, alternative 
splicing events can lead to the production of AR variants without a ligand-
binding domain (148, 188). These variants are thought to be constitutively 
active, even in the absence of a ligand. In addition, PCa cells in CRPC 
patients have been shown to produce hormones in an autocrine manner, 
thereby providing fuel for the AR (145, 150). This facilitated the 
development of Abiraterone acetate, which inhibits CYP17A1, an enzyme in 
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the androgen biosynthetic pathway. Finally, it has been proposed that AR 
signalling can also be cross-activated by other growth factors, such as 
epidermal growth factor (EGF) (204-206). 
It has been hypothesized that the abovementioned alterations in AR 
signalling affect AR-mediated transcription and result in a different 
transcriptome, which drives the disease (Figure 7). For example, it has been 
shown that AR chromatin occupancy is more intimately associated with 
promoter regions in late state CRPC than in normal prostate tissue or 
localised disease, and that AR regulates a different set of target genes (203). 
In recent years, various other TFs and signalling networks have been shown 
to interact with and influence the AR, and the most important ones will be 
discussed in the following. 
ETS transcription factors 
 
In 2005, highly prevalent fusions between the 5’-UTR of androgen-regulated 
transmembrane serine protease TMPRSS2 and two members of the ETS 
family of TFs, ERG and ETV1 was described (189). Other fusions, such as ETV1 
and ETV5 with SLC45A3, or ETV1 with HMGN2P46, were found soon 
thereafter (207, 208). All of these fusions put the respective ETS TF under the 
transcriptional control of the AR. The clinical incidence of the most frequent 
fusion, TMPRSS2-ERG, exceeds 50% and was initially thought to be 
associated with an aggressive, invasive subtype of PCa and shorter time to 
BCR (191, 209, 210). Subsequent studies, however, failed to show a 
prognostic value (211, 212), or even reported TMPRSS2-ERG to be a 
predictor of favourable outcome (213, 214).  
Mechanistically, the TMPRSS2-ERG fusion is thought to repress the 
differentiation programs of cells into luminal and neuroendocrine types 
(215, 216). Furthermore, ETS-fusion TFs have been shown to influence the 
activity of the AR, albeit with differing effects and depending on the identity 
of the ETS factor. ERG has been shown to repress AR signalling by inhibiting 
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AR expression and direct binding to the receptor at specific genomic loci 
(201, 217). In a mouse model with a homozygous PTEN deletion, however, 
ERG markedly amplified AR chromatin binding and signalling (218). This 
remarkable difference stresses the importance of context-specificity and the 
need to carefully assess the composition and activity of transcriptional 
networks and signalling pathways. In the same models, ETV1 has been 
shown to amplify AR signalling and confer an aggressive phenotype (217, 
218). In a different model, however, ETV1 has been shown to antagonize AR 
action (219), another example of context-specificity. GABPα, another 
member of the ETS family commonly overexpressed in PCa, has been shown 
to modulate the expression of a subset of AR target genes, to mediate an 
aggressive phenotype and to modulate sensitivity to AR antagonists (220). 
In addition to their interplay with the AR, ETS family members have also 
been shown to interact with other TFs and signalling networks (Figure 8). 
Specifically, TMPRSS2-ERG has been shown to cooperate with the PI3K 
signalling pathway (221), which is intriguing since a negative regulator of 
this pathway, PTEN, is frequently lost in PCa. Furthermore, the loss of the 
tumour suppressor NKX3.1, which occurs early in prostate carcinogenesis 
(Chapter 1.5.1), has been shown to promote the fusion of TMPRSS2 and 
ERG (222). Lastly, TMPRSS2-ERG drives the expression of MYC with 
concomitant repression of epithelial differentiation genes (216). 
Forkhead transcription factors 
 
The superfamily of forkhead TFs (FOX) contains more than a 100 distinct but 
structurally related members, classified into 18 subfamilies, such as A, O and 
P (223, 224). The defining feature of this protein family is the forkhead 
domain, a winged helix DNA binding domain (225). Members of this family 
are often termed ‘pioneer factors’ for their ability to bind compacted 
chromatin and make these regions accessible for other chromatin binding 
factors (226). Mutations in and loss of members of this family, specifically 
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FOXA1, FOXO1, FOXO3 and FOXP1, are commonly observed in PCa, with an 
incidence of approximately 3-9% (165, 166). Especially one member, FOXA1, 
has been extensively studied in breast cancer, another hormone-dependent 
cancer. There, FOXA1 is essential for proliferation and normal AR and 
estrogen receptor (ER) alpha activities (227, 228), and its overexpression is 
associated with favourable outcome (229, 230). 
In PCa, however, FOXA1 is overexpressed in metastatic PCa and CRPC and 
associated with poor prognosis (231-233). Mechanistically, FOXA1 has been 
shown to influence AR chromatin binding and signalling (Figure 8). 
Specifically, FOXA1 downregulation triggered a massive reprogramming of 
the AR, both assisting and antagonizing its activity at certain loci (233, 234). 
In another setting, FOXA1 overexpression facilitated and reprogrammed AR 
chromatin binding and increased sensitivity to DHT-induced proliferation 
(235). Additionally, FOXA1 has been reported to act as a cofactor of AR in a 
model of CRPC, facilitating androgen-independence and cell cycle 
progression (236). 
On the other hand, another member of the forkhead family, FOXO1, is 
frequently lost in PCa and thus considered a candidate tumour suppressor 
(237). Mechanistically, it has been shown to mediate PTEN-induced 
repression of AR activity, both of full length and splice-variants (238-240). 
Furthermore, Docetaxel- and Cabazitaxel-induced inhibition of the AR in 
CRPC patients is thought to be dependent on FOXO1 (241). Another 
example of the forkhead family, FOXP3, is also a candidate tumour 
suppressor frequently downregulated in PCa, and has been reported to 
transcriptionally repress the oncogene MYC (Figure 8) (242). 
Homeobox-containing proteins 
 
Several homeobox-containing TFs have been implicated in prostate 
function as well as PCa initation and progression. Especially NKX3.1 plays a 
vital role in normal prostate development and function (243, 244), albeit 
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other functionally redundant members of the NK family appear to be able to 
compensate for NKX3.1 loss (245). During development, its initial 
appearance precedes that of the AR, although its maintenance requires AR 
activity (246, 247). Expression of NKX3.1 is lost in many cases of PIA and up 
to 85% of PIN through LOH (8p21) and potentially other mechanisms (193, 
248-250). In addition, loss of expression correlates with tumour progression 
(195). Interestingly, elevated NKX3.1 expression has been observed in BPH, 
which further highlights the profound differences between BPH and 
precursors of PCa (251). 
In mouse models, loss of NKX3.1 is sufficient to induce PIN but not PCa (252, 
253). Furthermore, it has been shown that inflammatory cytokines are able 
to suppress the expression of NKX3.1 via phosphorylation and 
ubiquitinylation (254). Mechanistically, NKX3.1 controls the expression of 
anti-and pro-oxidative enzymes (255). Additionally, NKX3.1 has been shown 
to interact with topoisomerase I and this interaction enhances DNA repair 
(140, 256). Thus, loss of NKX3.1 might impair this critical process and lead to 
an increase in illegitimate recombination and genomic instability (222), 
which are prominent features of PIN and early PCa. It has been postulated 
that NKX3.1 is a driver of differentiation and a haploinsufficient tumour 
suppressor that acts as a gatekeeper gene for PCa initiation (139). 
As mentioned above, NKX3.1 knockout induces PIN but not PCa. Loss of 
NKX3.1 function, however, cooperated with loss of PTEN, resulting in a 
synergistic activation of Akt and accelerated onset of PIN and early stages of 
PCa (Figure 8) (257). Furthermore, PTEN loss has been reported to suppress 
NKX3.1 expression and conversely, NKX3.1 restoration inhibited Akt and AR 
signalling (258). Strikingly, AR drives the expression of NKX3.1 and a 
reciprocal feedback regulation between AR and PI3K/Akt signalling has 
been reported (see section on Phosphoinositide-3-kinase signalling 
below). These findings suggest a highly dynamic interplay between AR, 
NKX3.1 and the PI3K/Akt signalling pathway. Both NKX3.1 and the 
oncogene MYC are located on chromosome 8, which is frequently altered in 
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PCa (165-167). Strikingly, an inverse relationship between NKX3.1 and MYC 
has been reported, and both TFs have been shown to share a subset of their 
target genes (259). MYC overexpression reduces NKX3.1 levels and 
conversely, NKX3.1 can oppose MYC transcriptional activity (Figure 8) (259, 
260). 
Another homeobox-containing TF, HOXB13, is exclusively expressed in AR-
positive prostate cells and has been reported to suppress AR activity and 
reduce intracellular zinc levels (261, 262). Germline mutations in this gene 
have been shown to increase the risk for PCa (77). 
Phosphoinositide-3-kinase signalling 
 
The PI3K/Akt/mTOR signalling pathway is one of the most consistently 
altered pathways in human cancers and is known to regulate metabolism, 
inflammation, cell survival, motility and cancer progression (263). 
Phosphoinositid-3-kinases (PI3K) and specifically class I PI3K are a class of 
protein kinases, which can be activated by a multitude of signals, including 
phosphorylated receptor tyrosine kinases (RTK) and G protein-coupled 
receptors (GPCR) (264). Upon activation, PI3K phosphorylates 
Phosphoinositid-4,5-diphosphate PI(4,5)P2 to PI(3,4,5)P3, which serves as a 
docking site for downstream kinases, such as Akt. Once bound to PI(3,4,5)P3, 
Akt gets phosphorylated by PDK1. This phosphorylation turns on the 
catalytic domain of Akt and allows it to activate the mammalian target of 
rapamycin complex (mTORC1) via phosphorylation of proline-rich Akt 
substrate of 40kDa (PRAS40) and tuberous sclerosis protein 2 (TSC2). The 
activated mTORC1 complex drives a range of cellular processes, such as 
protein synthesis and cell survival through a range of downstream effectors, 
including ribosomal S6 kinase (S6K1) and eIF4E-binding proteins (Figure 9). 
PI3K signalling is negatively regulated by the tumour suppressor 
phosphatase and tensin homolog (PTEN). This phosphatase 
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dephosphorylates PI(3,4,5)P3 back to PI(4,5)P2, which inactivates the 
pathway (265, 266). 
 
 
Figure 9. The Phosphoinositid-3-kinase signalling pathway 
 
The Phosphoinositid-3-kinase (PI3K) signalling pathway drives key cellular processes, such as 
translation, cell growth, proliferation, ribosome biogenesis and various metabolic pathways. A variety 
of receptor tyrosine kinases (RTK) or G-protein couple receptors (GPCR) can activate PI3K, which in turn 
phosphorylates PIP2 to PIP3. PIP3 serves as a docking station for Akt, which is phosphorylated by PDK1. 
The now active Akt phosphorylates a range of downstream targets, including tuberous sclerosis protein 
2 (TSC2) and proline-rich Akt substrate of 40kDa (PRAS40). This leads to activation of the mammalian 
target of rapamycin complex (mTORC1) complex, which in turn drives the abovementioned key cellular 
processes through a range of targets, including eIF4E-binding proteins (eIF4E) and ribosomal S6 kinase 
(S6K1). 
In PCa, the two most commonly altered components of this pathway are 
PIK3CA, the gene for PI3K, and the negative regulator PTEN. It is estimated 
that this pathway is upregulated in about 25-70% of all PCa, and alterations 
are more common in metastatic disease (161, 168). PI3KC is amplified and 
mutated in approximately 25-30% of PCa (165, 171), and PTEN loss and 
inactivating mutations occur in about 45-50% (165, 166, 169, 267). 
Interestingly, these two are in general mutually exclusive. 
The PI3K/Akt signalling pathway has been shown to interact with the AR 
and influence AR transcriptional activity. Specifically, a reciprocal feedback 
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regulation of the AR and the PI3K/Akt signalling pathway could be 
demonstrated in various murine and human models of PCa (268-270). PTEN 
loss and concomitant upregulation of the PI3K/Akt pathway reduced AR 
levels and transcriptional output. Conversely, inhibition or deletion of the 
AR activated Akt signalling (268, 269). Strikingly, combined pharmacological 
inhibition of PI3K and AR potently reduced tumour burden in a PTEN-loss 
mouse model (269). 
c-Myc 
 
The TF V-myc avian myelocytomatosis viral oncogene homolog or short c-
Myc (MYC) is part of the myc family of TFs, which comprises at least the four 
members c-Myc, N-Myc, L-Myc and S-Myc. It was first described in 1981 as 
the mediator of avian leucosis virus (ALV)-induced lymphoma (271). 
Subsequently, it has been reported that reciprocal fusions between MYC 
and either the immunoglobulin heavy, lambda or kappa loci are strongly 
associated with non-Hodgkin’s lymphomas (272-274). These fusions are 
thought to deregulate the expression of MYC and thus, the mutant 
transcriptome of MYC has been extensively studied in lymphomas (275-
277). The MYC-containing 8q24 locus has also been reported to be 
amplified or rearranged in a range of other cancers and cancer cell lines, 
including colorectal, lung and cervical (278-281). Thus, genome-wide MYC 
binding properties have been described for these cell lines and others 
through the ENCODE initiative (282), however,  with the striking exemption 
of PCa. MYC is also thought to play a vital role in embryogenesis and stem 
cell maintenance (283). Thus, MYC function in embryonic stem cells (ESC) 
has been characterised comprehensively (284, 285). In addition, MYC was 
one of the four TFs originally used to reprogram terminally differentiated 
cells back to induced pluripotent stem cells (iPS) (286), which further 
stresses its importance in stem cell maintenance. 
Mechanistically, MYC acts as a heterodimeric TF, requiring the presence of 
its partner protein MAX (287). The assembled MYC-MAX complex binds 
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consensus DNA sequences in the genome, so-called E-boxes with a 
canonical sequence CACGTG, and initiates the transcription of its target 
genes (288). The MYC-MAX complex is predominantly assembled in 
proliferating cells. In resting or differentiated cells, however, MAX often 
binds to inhibitory partners, such as MAD or MNT, and these complexes 
repress transcription (289-291) (Figure 10). It has recently been proposed 
that MYC might act as a non-linear and universal amplifier of virtually all 
genes in lymphocytes and ESC (292, 293). Contradictory to these findings, 
however, it has been shown that MYC is also involved in transcriptional 
repression, which has been proposed to work through the interaction of the 
MYC/MAX complex with MIZ1 (294-297) (Figure 10).  
 
 
Figure 10. Transcriptional activation and repression by MYC 
MYC is both involved in transcriptional activation and repression, and both processes require a distinct 
set of binding partners and cofactors. When activating transcription, MYC is bound to its partner 
protein MAX and generally located at gene promoters. The complex recruits and binds a subset of 
cofactors, including histone exchange factors (HEFs, e.g. p400), histone acetyltransferases (HATs, e.g. 
CBP or TIP60), DNA helicases (e.g. TIP48 or TIP49) and elongation factors (e.g. P-TEFb). MYC’s binding 
partner MAX, however, can also bind to MAD or MNT, and these complexes have been shown to inhibit 
transcription. Furthermore, the assembled MYC/MAX complex can bind to MIZ1 and elicit repressive 
functions this way, presumably through the recruitment of DNA methylases (DNMTs), such as DNMT3a. 
Both transcriptional activation and repression are achieved through the 
recruitment of distinct protein complexes. These include histone 
acetyltransferase complexes (containing P300, TIP60, GCN5, CBP and 
adapters, such as TRRAP) (298-303), histone exchange factors (P400) (304), 
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DNA helicases (TIP48, TIP49) (305, 306), TF elongation complexes (p-TEFb) 
(307, 308), and DNA-methyltransferases (DNMT3a) (309) (Figure 10). 
Interestingly and rather unusual for a TF, MYC is apparently not involved in 
RNA polymerase II recruitment and formation of the pre-initiation complex 
(310-312), but rather in the regulation of transcriptional pause release (313).  
 
As mentioned above, MYC binding profiles and transcriptional networks 
have been extensively studied in a variety of model systems. Despite great 
differences between cellular models, a core MYC-regulated network of cell 
cycle control, anabolic metabolism and biomass accumulation has emerged 
in recent years (Supplementary Paper IV) (314). This core network includes 
genes essential for cell cycle control, ribosomal components and 
metabolism (315-318).  Interestingly, these are also functions controlled by 
the AR in PCa (202). Strikingly, however, the studies focusing on MYC 
function in PCa are limited to studies confirming MYC’s involvements in 
ribosome biogenesis and glutaminolysis (319, 320), and most recently its 
impact on lipid metabolism (321). Hence, our understanding of MYC’s exact 
contribution to PCa initiation and progression remains limited.  
Clinically, the chromosome locus containing MYC (8q24) has been reported 
to be amplified in up to 40% of PIN and potentially PIA (183, 322), making it 
an early event in prostate carcinogenesis, which predicts poor outcome 
(323, 324). Although the MYC gene in 8q24 is not always amplified itself, 
enhancer elements in commonly amplified upstream regions have been 
shown to increase MYC expression (325). Furthermore, elevated MYC 
protein levels are highly prevalent in PIN precursor lesions and thus 
constitute an early alteration in PCa (186). However, a clear correlation 
between 8q24 gain and MYC mRNA and/or protein levels could not always 
be shown (186), which highlights an important characteristic of MYC 
regulation. For example, there have been various reports of transcriptional 
regulation of MYC in PCa models (216, 242). In addition, post-transcriptional 
(326, 327), and translational (328, 329) mechanisms have been shown to 
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affect MYC levels in other model systems and these mechanisms might also 
act in PCa. Furthermore, post-translational modifications, such as 
phosphorylation and glycosylation, have been reported. For example, it has 
been postulated in mouse fibroblasts and mammary cells that 
phosphorylation at serine residues 62 and 71, or threonine 58 increases 
MYC’s transcriptional activity and might alter binding specificity (330, 331). 
In prostate models, it has been shown that phosphorylation at serine 373 
impairs MYC activity and that glycosylation influences stability of the 
protein (332, 333).   
In normal prostatic tissue, ectopic MYC overexpression immortalises cells, 
facilitates castrate-resistant growth and induces PIN and early-stage PCa in 
mouse models (260, 334). In this mouse model, MYC overexpression also 
repressed NKX3.1 (260), and conversely, MYC’s transcriptional activity is 
repressed by NKX3.1 (259). PTEN loss has been shown to drive MYC 
expression in cooperation with the MAPK signalling pathway (335). MYC 
expression is increased through TMPRSS2-ERG activity (216), and 
interestingly repressed by AR (336). In breast cancer cells, the AR has been 
reported to drive the expression of MYC, which in turn amplifies the 
transcriptional output of the AR (337). Notably, however, in PCa the effect of 
altered MYC expression on AR activity has thus far not been elucidated. 
Merely one review suggested that MYC knockdown might increase the 
expression of AR target genes (338). 
Challenges and opportunities 
 
As can be seen from the previous chapters, PCa is a highly complex and 
heterogeneous disease driven by a multitude of genomic alterations. 
Paradoxically, however, the focus of therapeutic intervention lies almost 
exclusively on the AR and AR signalling. Thus, studying the interplay of 
intracellular signalling pathways and transcriptional networks beyond the 
AR bears great potential for a better understanding of the disease and is 
likely to result in new treatment options. For example, this could happen 
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through repurposing of biomarkers or drugs used to treat other cancers, 
where these TFs have been defined as the main drivers. Defining the 
dominant TFs and networks in a given tumour will help to predict the 
activity of target pathways and concomitantly sensitivity to inhibitors 
(personalised medicine). With this in mind, the focus of this work will be to 
define the role of MYC in PCa and its influence on AR activity. 
However, there is a range of fundamental challenges that researchers need 
to overcome. As mentioned above, the gold standard for defining 
transcriptional networks of a given factor is a combination of ChIP-seq and 
gene expression analysis (Chapter 1.5.3). This requires the ability to alter 
the activity of the factor in question in a reliable and optimally absolute 
manner, i.e. on/off state. For nuclear hormone receptors, such as the AR or 
ER, this can been achieved through hormone-ablation and reintroduction. 
Other TFs, however, cannot be switched on and off this easily and this 
includes MYC. In addition, integrating both types of data in order to 
attribute changes in mRNA levels to changes in TF binding can often be 
challenging. Various TFs, such as MYC, have been reported to bind 
preferentially to proximal promoters and in this case, a direct regulation of a 
given target gene by the TF can generally be inferred. Other TFs, however, 
including the AR and the ER bind preferentially to intergenic and intronic 
regions, often several kilobases away from any gene. To tackle this issue, a 
variety of chromosome conformation capture methods have been 
developed (3C, 4C and 5C) to demonstrate the influence of distant TF 
binding on gene expression (339-341). However, these methods are 
experimentally demanding. 
Furthermore, changes in mRNA levels of a given target gene do not always 
predict changes in protein levels or activity since other factors, such as post-
translational modifications or protein half-life, influence these, too. Lastly, 
cell lines are often poor representations of in vivo tumours and thus, insights 
derived from these models need to be validated in a clinical setting. One 
approach to tackle this confounding challenge of PCa research has been the 
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development of three-dimensional organoid cultures, which more closely 
resemble the in vivo architecture of the prostate gland (342, 343). However, 
these models still lack the microenvironment and immune system 
component of patient tumours. Prostate tumours are often multifocal and 
heterogeneous, and are likely to contain a variety of cell types, including 
epithelial, stromal and immune cells. Cancer genomic approaches and 
transcriptional analyses usually use bulk tumour samples containing several 
thousand cells and this heterogeneity complicates analysis even further. 
Even if the majority of cells in a given tumour respond to a specific drug, this 
does not guarantee therapy response since it might be a previously 
undetected subclone that results in a lethal phenotype.  
This concludes the introductory part of this work. Based on previous 
research, this study set out with three distinct goals, which shall be 
described in more detail in the following section. 
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2. Aims of the study 
 
Defining transcriptional networks and especially transcriptional interplay 
will be crucial for the development of a more profound understanding of 
PCa and will ultimately lead to better detection and treatment options. 
Based on the current status of knowledge and technical expertise, this study 
aimed to tackle three distinct yet intimately connected issues (Figure 11).  
Part I (1) was purely a bioinformatics project and strived to assess the 
potential and significance of older gene expression datasets for current 
approaches (Figure 11). Array and sequencing platforms as well as 
technical principles have evolved and changed vastly over the past years. 
Thus, evaluating the biological durability of previously published datasets 
and results is a crucial factor in transcriptomics. We aimed to analyse older 
bulk expression data and develop a strategy to limit the impact of tumour 
heterogeneity and poorly defined cellular composition on subsequent 
analysis. Furthermore, experimental follow-up of postulated molecular 
concepts has often proven difficult due to their considerable sizes. Hence, 
we sought to develop a strategy to trim and refine complex transcriptomics 
data to make it more accessible to experimental and clinical follow-up. 
Part II (2) and III (3) were closely connected and will make use of similar 
techniques and datasets (Figure 11). Using unbiased approaches, we aimed 
to define the transcriptional network of MYC in PCa. To this end, we 
modulated MYC activity by overexpression and created several ChIP-seq 
and gene expression datasets. These included ChIP-seq data for AR, MYC 
and various active and repressive histone marks (H3K4me1/3, 
H3K27me3/ac), and complementing expression array data at various 
timepoints. We then wanted to compare these data to and combine it with 
previously published experimental datasets and publicly available clinical 
data. The questions we sought to answer with this approach were as 
follows. 
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A. Which gene networks/pathways are controlled by MYC in PCa but 
independent of the AR? Can we identify a single MYC-driven 
pathway that, if inhibited, improves AR targeted therapies? 
B. What is the genome-wide relationship between the AR and MYC? 
Are there overlapping genomic regions/gene networks/pathways 
in PCa shared by MYC and the AR? If yes, does modulating MYC 
levels influence their expression? 
 
 
 
Figure 11. Aims of this study 
 
The aims for this study were threefold and marked with yellow circles. Part 1 was purely bioinformatics 
and independent of any wet lab work. Using an array of previously published clinical PCa datasets, the 
goal was to develop a novel approach to analyse and interpret these highly heterogeneous datasets. 
Sequencing techniques and their interpretation have developed a lot over the past years and the aim 
was to evaluate whether information derived from older datasets still holds up in newer datasets 
generated with more sophisticated methods. Part 2 focused on establishing a thorough definition of 
MYC-driven gene networks in PCa cells. ChIP-seq and expression arrays under MYC-manipulating 
conditions (overexpression and knockdown) were generated to define MYC’s transcriptional networks 
and combined with datasets from the ENCODE initiative and publicly available clinical datasets. Part 3 
made use of the previously established MYC-network and assessed overlaps with the AR-driven 
transcriptome. Both self-generated ChIP-seq and expression array datasets for AR under MYC-
manipulating conditions and previous publications (Massie et al. and Yu et al.) as well as publicly 
available clinical datasets were used. Both purely MYC-driven and overlapping networks were be 
individually assessed for their clinical relevance and therapeutic potential. 
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We then selected an interesting subset of these networks/pathways and 
assessed their clinical relevance in patient cohorts. Furthermore, we sought 
to evaluate their therapeutic potential by repurposing existing drugs in a 
variety of preclinical models (Figure 11). 
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3. Summaries of included papers 
 
The three main papers included in this work will be briefly summarized. For 
more details, please refer to the original papers attached at the end of this 
thesis. 
 
3.1 Paper I 
 
Meta-analysis of prostate cancer gene expression data identifies a 
novel discriminatory signature enriched for glycosylating enzymes 
Barfeld SJ, East P, Zuber V, Mills IG. 
BMC Med Genomics. 2014 Dec 31;7(1):513. 
 
In this study, we performed a meta-analysis of several clinical expression 
array and RNA-seq datasets. Most importantly, we sought to identify robust 
gene signatures that were statistically significant in both datasets generated 
in whole tissue, and laser-capture dissected material. If we were to find such 
signatures, we wanted to develop a strategy to refine and compare them to 
a point that would allow comfortable experimental or clinical validation. 
Typical sizes of clinically utilised gene expression signatures are currently in 
the range of 20-30 genes. 
We started with a relatively old and small whole tissue dataset (Varambally 
et al.), and initially defined differentially expressed genes in BPH versus 
localised, and localised versus metastatic disease patients. We then applied 
a novel bioinformatics approach (Pearson correlation combined with 
hierarchical clustering using the Ward agglomerative method) to these 
differentially expressed genes and constructed a gene co-expression 
network. This approach created four large gene signatures consisting of 
several hundreds of genes each. 
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Next, we applied these signatures to two other datasets, a larger whole 
tissue (Ramaswamy et al.) and a laser capture microdissected dataset 
(Tomlins et al.). We asked whether our four large gene signatures or any of 
their sub-signatures could discriminate between patient sample groups 
(ranging from PIN to hormone-refractory CRPC) in the three datasets. We 
continued with the smallest sub-signature that was capable of 
discriminating between benign tissue and localised PCa in all three datasets. 
This signature consisted of 71 genes and the majority of the genes within 
were downregulated in PCa compared to benign tissue. Strikingly, MYC was 
among the few genes upregulated in PCa. We validated the expression 
patterns of the signature in two newer datasets - The Cancer Genome Atlas 
Prostate Adenocarcinoma (TCGA-PRAD) and Taylor et al. - and found it to be 
consistent with the previous three sets.  
Most biomarkers currently in use or under evaluation are overexpressed 
transcripts. Since the co-expression signature only contained few 
overexpressed genes, we went back to the originally defined differentially 
expressed genes in the Varambally et al. dataset, but only focused on 
overexpressed transcripts this time. In total, there were 97 overexpressed 
genes, which we refined using the Oncomine online compendium of 
expression array data. After applying a stringent threshold, we continued 
with a set of 33 genes that were consistently overexpressed among a broad 
range of PCa datasets. This list contained genes with a well-established role 
in cancer, such as MYC and ERG, but was clearly dominated by one 
metabolic pathway, O-glycan biosynthesis. Finally, we applied this signature 
to another dataset (Grasso et al.) and assessed its ability to discriminate 
between benign tissue, localised PCa and metastatic PCa. We found that the 
signature outperforms the discriminatory potential of AR, ERG and PSA 
(KLK3) in all comparisons. 
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3.2 Paper II 
 
Myc-dependent purine biosynthesis affects nucleolar stress and 
therapy response in prostate cancer 
Barfeld SJ, Fazli L, Persson M, Marjavaara L, Urbanucci A, Kaukoniemi KM, 
Rennie PS, Ceder Y, Chabes A, Visakorpi T, Mills IG. 
Oncotarget. 2015 May 20;6(14):12587-602. 
 
Our goal for this study was to use a global and unbiased approach to define 
MYC-regulated transcriptional networks in PCa. We combined in vitro and in 
vivo expression data, using an inducible MYC-overexpressing cell line model 
(LNCaP MYC), and co-expression analysis of clinical expression data (Taylor 
et al.), respectively. Both of our approaches revealed strikingly similar 
pathway enrichments, indicating that MYC-regulated genes are highly 
conserved between tissues and cell lines. The most significantly enriched 
pathways were ribosome biogenesis and several metabolic pathways, 
including purine, pyrimidine and amino acid metabolism. 
We decided to focus on the compact purine de novo biosynthesis pathway 
and confirmed its direct regulation by MYC in PCa cell lines using qRT-PCR 
and ChIP. Strikingly, the AR was not involved in the transcriptional 
regulation of the genes in the pathway. 
Next, we confirmed the clinical relevance of purine de novo biosynthesis. We 
interrogated the Oncomine online compendium of expression array data 
and focused on the two most consistently overexpressed genes in the 
pathway, PAICS and IMPDH2. We validated their overexpression at the 
mRNA and protein levels in two independent patient cohorts using clinical 
qRT-PCR and IHC, respectively.  
Subsequently, we applied siRNA-mediated knockdown to determine, 
whether PAICS or IMPDH2 were essential for PCa cell growth. Whilst PCa 
cells were largely unaffected by PAICS knockdown, IMPDH2 knockdown 
significantly impaired PCa cell growth. We went on to treat PCa cells with a 
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clinically approved IMPDH2 inhibitor, mycophenolic acid (MPA), and 
observed a dose-dependent reduction in cell viability. Furthermore, we 
discovered additive effects of IMPDH2 knockdown and MPA with currently 
prescribed anti-androgens and androgen synthesis inhibitors. We 
confirmed the specificity of MPA and reported that IMPDH2 inhibition 
induces nucleolar stress, activation of p53 and tumour-suppressive miRNAs, 
and concomitantly a feedback downregulation of the regulator of the 
pathway, MYC. 
 
3.3 Paper III 
 
Overexpression of c-Myc antagonises transcriptional output of the 
androgen receptor in prostate cancer 
Barfeld SJ, Urbanucci A, Fazli L, Rennie PS, Yegnasubramanian V, de Marzo 
AM, Mills IG. 
Manuscript 
 
For this study, we performed extensive ChIP-seq and gene expression 
analyses for AR, MYC and various active and repressive histone marks to 
characterize the impact of MYC overexpression in LNCaP MYC cells. We 
showed that AR and MYC co-occupy a substantial number of genomic loci 
amounting to approximately 25% of all AR and 30% of all MYC binding sites. 
MYC overexpression, however, did not significantly alter the AR binding 
profile or potency.  Interestingly, the AR/MYC co-occupied sites resembled 
typical AR enhancer binding sites as they were largely intronic or intergenic, 
and exhibited high levels of histone marks characteristic for enhancer 
regions. Notably, the forkhead factor and pioneering factor, FOXA1 
appeared to be highly enriched at AR/MYC overlapping binding sites. 
Next we assessed the effect of MYC overexpression on androgen-induced 
gene expression. Surprisingly, we found that MYC mainly antagonised AR 
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signalling, which was in contrast to a recent breast cancer study, in which it 
amplified it. These findings were corroborated by the observation that MYC 
overexpression reduced the amount of active histone marks characteristic 
for enhancers (H3K4me1) and increased the number of repressive 
H3K27me3 marks. Furthermore, siRNA-mediated depletion of MYC led to 
de-repression of AR target genes. 
Subsequently, we integrated both our ChIP-seq and expression array data 
and found that AR target genes that were antagonized by MYC were 
enriched for AR/MYC overlapping peaks in their vicinity. We validated our 
ChIP-seq and microarray predictions using ChIP qPCR and qRT-PCR, 
respectively. In addition, we also showed that the protein levels of multiple 
antagonized AR targets are significantly reduced. We then moved on to 
validate the antagonistic relationship of MYC and two AR target genes, KLK3 
and GNMT, in an established patient cohort consisting of patients with BPH, 
localized PCa and CRPC. Strikingly, we found that with increasing levels of 
MYC protein, both KLK3 and GNMT expression decreased.
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4. Methodological considerations 
 
The most widely applied methods in the included publications and their 
advantages and disadvantages as well as potential alternatives will be 
briefly discussed in this section. 
 
4.1 In vitro cell line models 
 
In vitro cell line models are common tools for scientists and although they 
share many characteristics of patient tumours and are a useful starting point 
for PCa research, they have several inherent flaws that limit their 
translational potential. For example, cell lines are usually grown on plastic 
dishes using a defined composite medium, which hardly resembles the 
complex three-dimensional nature of an in vivo tumour and its 
microenvironment. 
In our studies, we mainly worked on two widely used androgen-responsive 
and AR-expressing PCa cell lines, the LNCaP and VCaP lines. The LNCaP line 
was derived from a metastatic lesion to the supraclavicular lymph node of a 
Caucasian CRPC patient (344, 345). It has been extensively characterised and 
remains one of the most commonly used in vitro model systems for PCa 
research. Importantly for the analysis of transcriptional networks, LNCaP 
harbour an ETV1 fusion and PTEN LOH (161). VCaP cells were derived from a 
metastatic lesion to a lumbar vertebral body of a patient with CRPC (346). 
These cells contain a TMPRSS2-ERG fusion, one of the most frequent 
alterations in PCa (Chapter 1.5.3). The LNCaP-abl subline used in Paper II 
was created by culturing the parental LNCaP line in androgen-depleted 
medium for 87 passages and exhibits Lastly, we worked on a transgenic 
inducible MYC-overexpressing LNCaP derivative, termed LNCaP MYC. This 
cell line was previously published (346), and we performed extensive 
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timecourses to optimize our experimental conditions (see supplementary 
data in Paper II). 
 
4.2 siRNA-mediated knockdown 
 
To assess the relevance and function of a variety of genes, we reduced the 
expression of these genes in cell lines using small interfering RNAs (siRNAs). 
The underlying principle of RNA interference was first described by Fire et al. 
in 1998 and later awarded with the Nobel Prize in Physiology or Medicine 
(347). siRNAs were first described in detail in 1999 and shortly thereafter 
utilized in cell culture experiments to knockdown the expression of target 
genes (348, 349). In principal, cells are transfected with double-stranded 
siRNA molecules, which are processed by a variety of cellular proteins, 
including Dicer, Argonaute proteins, RISC, Drosha, TRBP and PACT (350). 
This results in degradation or block of translation of the target mRNAs and 
concomitant reduction in protein levels. 
Naturally, the technique comes with a range of possible drawbacks. Most 
importantly, siRNAs may bind unspecifically, which might reduce the 
expression of non-target genes. To overcome this, appropriate control 
experiments were used (non-targeting control siRNAs), and whenever 
possible, at least two different siRNAs targeting the same gene were used 
(IMPDH2 in Paper II). Another issue is time point selection since mRNA and 
protein levels do not necessarily correlate, and are influenced by a range of 
factors, including post-translational modifications and protein half-life. 
Thus, we always validated knockdown efficacy at both mRNA and protein 
level (MYC, IMPDH2, PAICS in Paper II) after conducting time courses. 
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4.3 RNA isolation and gene expression analysis 
 
Global gene expression analysis can be performed in a variety of ways. Most 
commonly, expression arrays or RNA-seq are being used to determine the 
expression status of a broad range of genes in an unbiased manner. Both 
require high quality RNA and thus we used Qiagen’s RNeasy kit, which is 
widely used for these applications. Furthermore, RNA integrity was always 
validated using Agilent’s Bioanalyzer system and spectrophoto-
/fluorometric methods where applicable (NanoDrop or Qubit systems). 
Preparation of biotin-labelled cDNA for hybridization on expression arrays is 
largely standardized and was performed by the genomics core. For 
expression arrays, various platforms exist and these include but are not 
limited to Affymetrix, Agilent and Illumina. Both probe sequences and 
genome coverage differ between the platforms, which regularly leads to 
issues when trying to compare datasets from different platforms. Thus, not 
all genes were covered in all platforms analysed in Paper I. In Paper II and III, 
we used Illumina Human HT-12 Expression BeadChips microarrays to create 
our own datasets.  
Expression array analysis 
 
Downstream analysis of expression array data requires extensive 
bioinformatics knowledge but due to the advanced nature of the technique, 
analysis pipelines are largely standardised. However, authors have used 
different algorithms to define differentially expressed genes or alternatively 
varying levels of fold change since no obligatory consensus exists. A range 
of third-party open-source software has enabled wet-lab scientists to 
perform these analyses themselves. For example, we used the freely 
available open source software J-Express (http://jexpress.bioinfo.no/site/), 
which allowed for a broad range of commonly used analysis procedures, 
such as standard normalization commands, fold change analysis and 
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hierarchical clustering (351). Other freely available software used included 
Cluster 3.0 (352), web-based Venn diagram creators (e.g. 
http://bioinfogp.cnb.csic.es/tools/venny/) and various functional annotation 
tools, such as DAVID or genecodis (353, 354). Furthermore, unbiased gene 
set enrichment analysis (GSEA) without prior data processing was 
performed using a web-based tool created by the Broad Institute 
(http://www.broadinstitute.org/gsea/index.jsp) (355). In general, we always 
made sure to validate our microarray predictions using qRT-PCR. 
 
4.4 Chromatin immunoprecipitation 
 
ChIP is a technique commonly used to map protein-DNA interactions and 
was first described in 1988 (356). Briefly, protein-DNA complexes are fixed 
using a suitable crosslinker, e.g. formaldehyde. After quenching, washing 
and cell lysis, cellular chromatin is sheared with an ultrasonic shearing 
device to an appropriate size range (usually 200 to 500bp). Subsequently, 
the fragmented chromatin is precipicated with the antibodies of choice, 
which are usually pre-bound to magnetic or agarose beads. The next day, 
bead-antibody-protein-DNA complexes are washed and crosslinking is 
reversed. Precipitated DNA sequences are validated after DNA clean-up 
using either qRT-PCR, microarrays or high-throughput sequencing (ChIP-
seq) (357). 
The technique has several potential pitfalls and issues researchers must be 
aware of. First and foremost, appropriate choice of antibody is crucial. 
Naturally, integrity and abundance of precipitated chromatin highly 
depends on antibody quality. Thus, only properly validated ChIP-grade 
antibodies, which had been experimentally validated in other studies, were 
used in our ChIP reactions in Papers II and III. Furthermore, we always 
included suitable controls, such as non-specific IgGs and total input control, 
to establish background signals. In terms of materials, magnetic beads are 
superior over their agarose/sepharose counterparts regarding background 
Methodological considerations 
 
 
57 
and handling, and virtually all research groups exclusively use those. Both 
crosslinking and sonication times require optimization and optimal time 
points vary between factors and cell lines. Therefore, we always ran 
optimization experiments for these conditions.  
When ChIP qPCR was used to validate precipitated DNA sequences, we 
made sure to use appropriate positive and negative genomic control 
regions. These were based on previously published datasets or datasets 
from the ENCODE consortium, which are publicly available, for example 
through the UCSC genome browser (http://genome.ucsc.edu/). We always 
included melting curves for the primer pairs to ensure specific amplification. 
Data presentation for ChIP qPCR is not standardized but displaying the data 
as either ‘% of input’ using the formula 2^(ct input-ct ChIP) or ‘fold over IgG’ 
using 2^(ct IP-ct IgG) are commonly used approaches.  
ChIP-seq and data analysis 
 
ChIP-seq requires the precipitated material to be processed to sequencing 
libraries compatible with the desired sequencing platform (usually Illumina 
or SOLiD based systems). During library preparation, the DNA is end 
repaired, ligated to barcoded sequencing adapters and amplified by PCR 
prior to HTS. Although this process has largely been standardized (Illumina 
TruSeq kits), it is nonetheless crucial to optimize the amount of PCR cycles 
to avoid overamplification and concomitant underrepresented libraries.  
For data analysis in Paper III, we combined the expertise of bioinformatics 
collaborators and the open-source web-based framework Galaxy in its 
various instances. Galaxy provides wet-lab scientists without programming 
knowledge with a means to perform their own basic and advanced analyses 
of ChIP-seq data (358, 359). Data analysis is complicated by the lack of a 
clear consensus analysis pipeline or publication requirements. Furthermore, 
the amount of quantitative information that can be derived from direct 
comparisons between treatment conditions in ChIP-seq experiments is still 
under debate. This is because multiple steps in the library preparation 
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process, such as PCR amplification or clustering, might mask biological 
differences. Recently, various approaches including novel bioinformatics 
normalisation steps and spike-in strategies have been developed to 
improve the analyses procedure (360-362). However, no clear consensus 
strategy currently exists and thus we tried to limit the conclusions drawn 
from our quantitative analyses performed in Paper III.  
The ENCODE consortium has attempted to introduce a gold standard for 
the publication of ChIP-seq data to increase reproducibility and data quality 
but so far no obligatory consensus has been established (363). In general, 
we adhered to the ENCODE guidelines and always performed and present 
overlaps of our datasets with previously published sets to increase 
confidence in data quality and analysis procedure (Paper III). Lastly, 
experimental validation of bioinformatics predictions using ChIP qPCR was 
always included for a broad range of loci. 
In Paper III, we also included a recently published modification of the 
original ChIP-seq protocol, termed ChIP-exo (Supplementary Paper V) 
(364). ChIP-exo incorporates two exonuclease digestion steps and on-bead 
library preparation and these steps are thought to narrow peak width and 
reduce hands-on time during library preparation, respectively. A more in 
depth comparison of ChIP-seq and ChIP-exo, and a detailed experimental 
procedure can be found in the appendix (Supplementary Paper V). 
 
4.5 Clinical samples 
 
Tumour heterogeneity and multifocality, as well as cellular composition and 
integrity of the samples are confounding challenges when operating on 
patient-derived specimens and these need to be carefully addressed. Due to 
the translational nature of our research, all three papers included in this 
thesis made use of clinical samples. In Paper I we focused on previously 
published clinical expression data derived from patient tumours. Since this 
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paper is a meta-analysis of previously published datasets, it was not in our 
power to control sample quality and integrity. In Papers II and III, however, 
we used qRT-PCR and IHC on our own patient cohorts.  
Immunohistochemistry 
 
Paper II evaluated the protein levels of PAICS and IMPDH2 in a cohort 
consisting of a total of 194 PCa specimens obtained from the Vancouver 
Prostate Center. This patient cohort has previously been used in various 
other publications (202, 365), and thus our confidence in sample quality and 
integrity was high. More information on antibody validation and quality 
control can be found in the material and methods section of Paper II. In 
Paper III, we validated the expression of MYC, KLK3 and GNMT in the same 
patient cohort and more information can be found in the supplemental 
section of this paper. 
Clinical real-time PCR 
 
In Paper II, we performed qRT-PCR on a total of 55 clinical samples derived 
from patients with BPH (15), localised PCa (27) and CRPC (13). This patient 
cohort has also been used in numerous publications (366-368), and thus we 
were assured of its quality and integrity. The exon-spanning primers 
targeting PAICS and IMPDH2 used in the paper were carefully assessed in 
their specificity using melting curves and gel electrophoresis. 
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5. Discussion 
 
In this chapter, the work conducted in the three summarised papers will be 
discussed and put into context. For a more detailed discussion of the 
individual results, the reader is advised to consult the discussion sections of 
the respective papers. 
 
A novel co-expression approach reveals gene signatures capable of 
clustering patient samples 
 
In Paper I, Meta-analysis of prostate cancer gene expression data identifies a 
novel discriminatory signature enriched for glycosylating enzymes, we 
performed extensive meta-analyses of several publicly available gene 
expression datasets (369-371).  
Using a novel co-expression approach, we defined a compact gene 
signature (71 genes) that was capable of subclustering patient samples and 
validated it in two additional cohorts (167, 372). Interestingly, the signature 
mainly consisted of genes downregulated in PCa relative to BPH and was 
enriched for genes involved in smooth muscle contraction and focal 
adhesion. This high frequency of downregulated genes in epithelial tumour 
tissue relative to controls has previously been reported (373). Furthermore, 
numerous myosin components were present among the downregulated 
genes. It has been shown that PCa progression depletes stromal 
components from the tissue and this might explain this observation (374). 
Strikingly, MYC was among the only four genes that were significantly 
overexpressed in this signature. 
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Enzymes involved in glycosylation are highly upregulated within the 
co-expression gene signatures 
 
From a biomarker perspective, genes that are downregulated during the 
course of a disease are less attractive than upregulated ones. Thus, we 
shifted our focus to 33 genes that were consistently upregulated in our co-
expression analyses and the Oncomine database (375). Kyoto Encyclopaedia 
of Genes and Genomes (KEGG) pathway enrichment revealed glycosylation 
to be the most significantly enriched pathway with four enzymes involved 
in glycosylation contributing to the enrichment.  
Glycosylation describes an enzyme-catalysed reaction in which glycans, 
sugar molecules of varying complexity, are attached to other molecular 
structures, most commonly proteins or lipids. Depending on composition, 
this creates a variety of different molecules, including glycoproteins, 
proteoglycans and glycolipids (376). Glycosylation influences protein 
folding and stability, cell-cell interactions, and proteoglycans are a crucial 
part of the ECM. The two most abundant forms of glycosylation are N-
linked, where the glycan is attached to a nitrogen atom of asparagine, and 
O-linked, where the glycan is attached to an oxygen atom of serine or 
threonine (377, 378).  
Notably, UAP1 is the final enzyme of a metabolic pathway called 
hexosamine biosynthetic pathway (HBP), which produces UDP-N-
acetylglucosamine (UDP-GlcNAc) (379). UDP-GlcNAc is the starting molecule 
for more complex glycans that are subsequently attached to target proteins 
via N-linked and O-linked glycosylation in the endoplasmic reticulum (ER) 
and the Golgi apparatus. The HBP has been described as an integration 
point for multiple metabolic pathways, including glycolysis, glutaminolysis 
and nucleotide biosynthesis. Hence, the activity levels of the HBP might 
reflect the overall energy status of a given cell. Strikingly, UAP1 has recently 
been reported to be overexpressed early in PCa and to protect against 
inhibitors of N-linked glycosylation (380). The high prevalence of 
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glycosylation enzymes in our signature merits future investigation into this 
exceedingly interesting metabolic pathway. 
 
A compact molecular signature containing MYC discriminates between 
benign cases, localised and metastatic prostate cancer 
  
To validate the discriminatory potential of our 33 gene signature, we 
applied it to a total of three different datasets (Taylor et al., TCGA-PRAD and 
Grasso et al.) and assessed its ability to cluster patients into different disease 
stages. We compared the performance of our signature to the classical PCa 
classifiers AR, KLK3 and ERG. Strikingly, our signature discriminated between 
BPH, localised PCa and metastatic samples with excellent sensitivity and 
specificity as reflected in area under the curve (AUC) values ranging from 
0.95 to 0.99. No individual gene was able to discriminate with such a high 
sensitivity and specificity and this highlights the translational potential of 
multigene signatures. Notably, various multigene signatures have recently 
been developed and applied in diagnostics to improve patient stratification 
and treatment decisions (e.g. GenomeDx Decipher) (381-383). Intriguingly, 
multiple genes in our signature have been postulated as PCa biomarkers in 
blood or urine. These include ERG, AMACR, CRISP3, GDF15, TDRD1 (384, 
385), and most prominently PCA3, which is already in clinical use (386). 
Interestingly, out of the 33 genes in our signature, five were TFs – SIM2, 
DLX1, HOXC6, ERG and MYC. Increased levels of SIM2 have recently been 
reported as a novel marker of aggressive PCa (387). DLX1 is part of a 
candidate gene panel for the early diagnosis of PCa and strikingly, this panel 
also includes HOXC6 (388). Furthermore, other homeobox factors, such as 
NKX3.1 or HOXB13 have well-established roles in PCa (1.5.3). ERG, which is 
frequently fused to the androgen-regulated gene TMPRSS2, has been 
studied extensively in PCa (1.5.3). Intriguingly, this was not the case for 
MYC, which will be the focus of the next parts of this discussion. 
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MYC directly controls purine de novo biosynthesis and other metabolic 
pathways in prostate cancer cells 
 
MYC was consistently overexpressed in a broad range of datasets used in 
Paper I and part of our 33 gene signature. However, surprisingly little was 
known about the biological consequences of elevated MYC levels in PCa. 
Thus, we went on to define MYC’s transcriptional networks in an unbiased 
manner. Our approach, which resulted in Paper II, was twofold. Firstly, we 
used a recently published inducible MYC-overexpression derivative of the 
LNCaP cell line, termed LNCaP MYC, and gene expression microarrays after 
short periods (5h and 12h) of MYC overexpression (389). Secondly, we 
revisited the Taylor et al. dataset and performed an in silico analysis using a 
similar strategy as in Paper I to define genes co-expressed with MYC in CRPC 
patients (167).  
Notably, both approaches revealed a strikingly similar pathway enrichment 
pattern enriched for biosynthetic processes, including ribosome biogenesis 
and various metabolic pathways, such as purine and pyrimidine 
biosynthesis. Interestingly, our findings were similar to previous reports 
from other models systems, such as lymphomas or embryonic stem cells 
(Supplementary Paper IV) (390, 391), suggesting that MYC is a driver of 
biomass accumulation and controls a core set of genes and networks, 
regardless of cell type. In PCa, MYC had previously been reported to drive 
ribosome biogenesis in PCa (320), and thus we focused on the second most 
significantly enriched pathway in both approaches, purine de novo 
biosynthesis.  
This pathway consists of six enzymes that catalyse the conversion from 
phosphoribosyl pyrophosphate (PRPP) to inosine-5’-monophosphate (IMP), 
which in turn is converted to adenosine-5’-monophosphate (AMP) or 
xanthosine-5’-monophosphate (XMP) via the activity of ADSS/ADSSL1 or 
IMPDH1/2, respectively. XMP in turn is converted to guanosine-5’-
monophosphate (GTP) (392). The de novo purine biosynthesis can be 
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regarded a supplemental metabolic pathway fuelling core cellular 
processes, such as DNA replication, transcription and energy budgeting. 
Non-dividing and differentiated cells generally rely on the purine salvage 
pathway for their purine needs and the de novo biosynthetic pathway is 
thought to be active only in dividing cells, such as cancer or stem cells (392). 
The compactness and potential specificity for rapidly dividing cells made 
the pathway an extremely attractive target to focus on. Furthermore, 
revisiting the Oncomine database revealed two members of this pathway, 
IMPDH2 and PAICS, to be consistently overexpressed among 16 other 
published clinical datasets (375).  
We then moved on to validate our in silico predictions in two PCa cell lines 
and found MYC to directly regulate five enzymes of the de novo biosynthesis 
(PPAT, GART, PFAS, PAICS and ADSL) plus one IMP-converting enzyme 
(IMPDH2). These enzymes responded to MYC overexpression and 
knockdown with increased and decreased mRNA and protein levels, 
respectively. Furthermore, they exhibited binding of MYC to their respective 
promoters as shown by ChIP qPCR experiments, which suggested a direct 
regulation. This strategy has been used before to confirm MYC’s role as a 
direct regulator of nucleotide biosynthesis in Burkitt’s lymphoma cells and 
of ribosome biogenesis in PCa cells (276, 320). Notably, the genes appeared 
to be independent of AR activity since androgen treatment did not alter 
mRNA or protein levels. 
 
PAICS and IMPDH2 are overexpressed in prostate cancer patients 
 
Our in vitro approach and the Oncomine database suggested that the de 
novo purine biosynthetic pathway was a clinically relevant metabolic 
pathway in PCa. To confirm these in vitro predictions in patients, we 
assessed the mRNA and protein levels of the two most consistently 
overexpressed enzymes in the pathway, PAICS and IMPDH2, in two different 
patient cohorts. Both cohorts had been used previously to assess the clinical 
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relevance of a variety of genes/proteins, including ZWINT1, FEN1, CAMKK2 
and TAF1 (202, 365, 368). We found PAICS to be upregulated at the mRNA 
level in CRPC and at the protein level both in localised PCa and CRPC. This 
was the first time PAICS expression was assessed in any cancer and our 
study suggested a strong potential for PAICS as a biomarker. SAICAR, the 
intermediate of the de novo purine biosynthetic pathway produced by 
PAICS has previously been implicated in the regulation of pyruvate kinase 
isoform M2, a potentially crucial enzyme for cancer cell growth in glucose-
limited conditions, which are commonly observed in solid tumours (393).  
Similarly, IMPDH2 mRNA and protein levels were elevated in CRPC and thus 
suggested potential for IMPDH2 as a PCa biomarker for late stage disease. 
The biomarker potential of IMPDH2 had previously been reported in 
colorectal cancer but our study was the first to assess IMPDH2 expression in 
PCa (394). 
 
Inhibition of IMPDH2 reduces proliferation and leads to nucleolar 
stress, p53 activation and induction of MYC-targeting miRNAs 
 
Next we determined whether PAICS or IMPDH2 were essential for PCa cell 
proliferation. Using siRNA-mediated knockdown, we observed a significant 
decrease in cell proliferation when IMPDH2 but not PAICS expression was 
reduced. Intriguingly, an uncompetitive inhibitor for IMPDH2, mycophenolic 
acid (MPA), is a clinically approved immunosuppressant (395), and we 
observed a dose-dependent reduction in cell viability in PCa cell lines. 
Interestingly, combinatory treatment with an established anti-androgen 
(Enzalutamide/MDV3100) or an androgen biosynthesis inhibitor 
(Abiraterone) resulted in additive effects. This further strengthened the AR-
independence of this metabolic pathway and merits further investigation 
into the clinical potential of MPA for the treatment of late stage PCa. This is 
particularly intriguing since several governmental agencies have started to 
collaborate with pharmaceutical companies to loosen intellectual property 
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restrictions with the goal of repurposing existing drugs for new diseases 
(396). The main advantage of this strategy is that the existing drug has 
already passed most basic clinical tests regarding general toxicity and other 
issues that commonly lead to failure during drug development. Examples of 
repositioned drugs currently in clinical trials for PCa treatment include 
Nelfinavir (originally an HIV drug) and Digoxin (originally developed for 
cardiac diseases) (397). MPA, however, due to its advanced age is no longer 
protected by any intellectual property restrictions and is a relatively cheap 
drug. Thus, the motivation for a clinical trial involving a combination 
treatment of MPA and AR-targeting drugs would be to lower the necessary 
doses of expensive AR-targeting drugs. This could dramatically reduce 
treatment costs and thus reduce the financial burden for the healthcare 
system. 
Mechanistically, we showed that MPA treatment reduced intracellular GTP 
levels but did not significantly alter the levels of other nucleotides. 
Furthermore, adding guanosine rescued the anti-proliferative effect and 
confirmed the specificity of MPA. Depleting cells of GTP has a range of 
physiological effects due to the wide-spread functions of nucleotides and 
particularly the nucleolus has been shown to be extraordinarily sensitive to 
GTP shortages. The nucleolar protein nucleostemin, also called guanine 
nucleotide-binding protein-like 3 (GNL3), is a positive regulator of cell 
proliferation and expressed in a variety of cancer and stem cells (398). GTP 
depletion leads to rapid degradation of GNL3 and nucleolar stress, and we 
were able to confirm these effects in PCa cell lines (399). Notably, coping 
with cellular stress is a hallmark of cancer cells (36), and being able to trigger 
a massive stress response in tumour cells might improve drug response in 
patients. Nucleolar stress has a multitude of downstream effects and 
amongst others, it triggers p53 stabilisation and concomitant cell cycle 
arrest, both of which we observed in PCa cells (400, 401). Strikingly, MPA 
treatment also led to a feedback downregulation of MYC, which at least in 
part appears to be mediated by the MYC-targeting microRNAs (miRs) 34b 
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and 145, which have previously been shown to reduce MYC levels in other 
PCa models (402, 403). In conclusion, MYC directly controls purine de novo 
biosynthesis and the conversion of IMP to XMP/GMP in PCa cell lines. 
Inhibition of IMPDH2, an IMP-converting enzyme inhibits proliferation, leads 
to nucleolar stress and sensitises cells to androgen-deprivation therapy. 
Notably, it also led to a feedback downregulation of MYC. This is particularly 
intriguing since MYC is overexpressed in a substantial proportion of PCa 
patients, and even after decades of research, no MYC inhibitor has been 
clinically approved yet. Thus, targeting MYC-dependent pathways instead 
might help to diminish the contribution of the TF to the malignancies and 
serve as a patient stratifier. A recent study has shown that approximately 
90% of CRPC cases harbour ‘clinically actionable’ molecular alterations, such 
as PI3K pathway, AR signalling or cell cycle control (164). However, the 
immediate clinical impact of inhibiting these molecular alterations in CRPC 
patients has been rather underwhelming so far. Including MYC-targeted 
therapies might significantly improve these numbers.  
 
MYC and AR share a substantial amount of overlapping binding sites 
 
After having established that MYC regulates a range of core metabolic 
processes in PCa cells that are independent of AR activity, we aimed to 
define the relationship between AR and MYC and evaluate whether both 
TFs share common targets or gene networks. It was recently shown in 
apocrine breast cancer cells that MYC levels were increased by androgen 
treatment and that MYC in turn amplified AR activity and transcriptional 
output in a positive feedback manner (337). To our surprise, however, 
androgen treatment of PCa cells did not increase but significantly decreased 
MYC levels and thus suggested a different relationship between these two 
TFs in PCa cells.  
As previously reported, MYC overexpression induced androgen-
independent growth of our LNCaP cell line model, which we used in Paper II 
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(260, 334, 389). Thus, we sought to investigate the role of ectopic 
overexpression of MYC on AR activity in LNCaP MYC cells. Firstly, we defined 
the global MYC and AR binding profiles using ChIP-exo after androgen 
treatment with or without MYC overexpression. ChIP-exo is a modification 
of the traditional ChIP-seq approach and incorporates two novel 
exonuclease reactions to narrow peak widths and refine signal to noise ratio 
(364). The overlaps between our AR and MYC datasets and previously 
published datasets in PCa and other cell lines ranged were substantial and 
gave us confidence in our experimental approach and analysis pipeline. We 
found that MYC overexpression did not significantly alter MYC or AR 
binding profiles, which might, however, be due to nature of ChIP-seq and its 
restrictions in terms of quantitative analyses (362). MYC overexpression did 
not redistribute MYC or AR binding sites and motif enrichments were similar 
in both conditions. Interestingly, MYC and AR shared 11,857 binding sites, 
which amounted to approximately 25% of all AR and 30% of all MYC sites. 
These sites were largely intergenic and intronic, and were highly enriched 
for FOXA1 binding (approximately 55%), which we confirmed by 
overlapping our sites with a previously published dataset for FOXA1 (404). 
This is the first time an overlap between MYC and FOXA1 has been reported 
and suggests the existence of a larger transcriptional complex containing 
AR, MYC and FOXA1. Furthermore, the average peak height of these 
AR/MYC overlapping peaks was significantly higher than for all AR peaks 
and this suggested that AR/MYC overlapping peaks were high-affinity 
binding sites for the AR.  
 
MYC overexpression alters global H3K4me1 and H3K27me3 levels 
 
MYC has recently been shown to correlate inversely with H3K27me3 levels, 
which in turn correlate with differentiation (405). Thus, we sought to 
evaluate the effect of MYC overexpression on global H3K27me3 levels using 
ChIP-seq in our model. In addition, we included three other histone marks in 
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our study, H3K4me1, H3K4me3 and H3K27ac, which serve as  markers for 
active enhancers and promoters (406). As with our ChIP-exo data for the AR 
and MYC, we compared our datasets to previously published datasets and 
observed substantial overlaps ranging from 45-100%. Upon MYC 
overexpression, the most striking differences were observed for H3K4me1, 
where increased MYC levels reduced the total number of peaks by 
approximately 20%, and for H3K27me3, where MYC overexpression 
increased the number by roughly 30%. This suggested that ectopically 
elevated MYC levels decreased the amount of active enhancers (H3K4me1) 
and increase the amount of condensed chromatin regions (H3K27me3) 
(406). 
Integration of our histone ChIP-seq data with the AR and MYC ChIP-exo 
datasets revealed that AR sites were predominantly associated with 
enhancer-like features (high H3K4me1 and H3K27ac) and MYC sites with 
those of active promoters (high H3K4me3 and H3K27ac). Strikingly, the 
AR/MYC overlapping sites resembled pure AR sites in their histone 
modification pattern (high H3K4me1 and H3K27ac) and neither AR nor MYC 
sites were significantly associated with H3K27me3. 
 
Overexpression of MYC antagonises AR-mediated transcription 
 
As mentioned above, MYC has been shown to amplify transcriptional 
output of AR-regulated genes in breast cancer cell lines (337). To evaluate 
the effect of MYC overexpression on AR-mediated transcriptional regulation 
in our model, we performed gene expression analysis under similar 
conditions as our ChIP-seq experiments (androgen stimulation alone or 
together with MYC overexpression). We used unbiased gene set enrichment 
analysis (GSEA) and found, as expected, a classic androgen signature 
(Nelson et al.) to be the top-upregulated gene set upon androgen 
stimulation (407). Upon MYC overexpression, we observed a range of typical 
MYC target signatures among the top-upregulated gene sets and this 
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confirmed the validity of our model system (408). Intriguingly, the top-
downregulated gene set when MYC was overexpressed was the 
abovementioned androgen signature, suggesting that MYC does not 
amplify but antagonise AR-mediated gene transcription in PCa cells. This 
was further corroborated by GSEA of previously published gene expression 
data that used siRNA-mediated knockdown of MYC (320). Correspondingly, 
MYC knockdown led to a significant upregulation of the Nelson androgen 
signature. We then looked at individual genes and found that a substantial 
amount of androgen-induced genes, roughly 25%, were antagonised by 
MYC overexpression while only about 1.5% were amplified. We subjected 
the antagonised genes to pathway analysis using KEGG and gene ontology 
(GO) and found a variety of metabolic pathways and transcriptional 
regulatory networks. Strikingly, UDP-N-acetylglucosamine biosynthesis, 
which we discussed in Paper I was among the pathways. Thus, MYC 
overexpression resulted in an increased number of condensed chromatin 
regions (H3K27me3), a decrease in active enhancers (H3K4me1) and 
primarily antagonised androgen-induced gene transcription. We then 
integrated our ChIP-seq and expression array datasets and found a 
significant enrichment of AR/MYC overlapping peaks in the vicinity of 
antagonised genes, which suggested a direct effect of MYC overexpression 
on these genes. However, establishing direct effects of distant TF binding 
on gene expression remains a challenge (Chapter 1.5.3 – Challenges and 
opportunities).  
 
MYC levels inversely correlate with antagonised AR targets in vivo 
 
Our list of antagonised genes included several AR targets that have 
previously been suggested as putative PCa biomarkers. These included 
SOCS2 and GNMT, which have both been shown to perform in opposite and 
contradictory directions in various studies (409-412). We validated the 
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antagonistic effect of MYC overexpression on these genes in our cell line 
model using ChIP qPCR, qRT-PCR and western blotting.  
Subsequently, we progressed to clinical samples and assessed the protein 
levels of MYC, KLK3 and GNMT in the same patient cohort we used in Paper 
II. As predicted by our cell line experiments, staining intensities for KLK3 and 
GNMT decreased with increasing MYC levels. Our findings suggest that the 
levels of putative protein biomarkers in biopsy samples depend not only on 
the activity of the AR but are also influenced by other TFs, such as MYC. The 
fusion between TMPRSS2 and the ETS TF ERG has been reported to suppress 
prostate cell differentiation and drive a more stem-like phenotype (215, 
216). Likewise, the repressive effect of MYC overexpression on a subset of 
AR-targets could be interpreted as a similar process, especially since MYC 
has been shown to drive stem-cell like phenotypes and control the balance 
between differentiation and self-renewal in different models (283, 413). This 
could help to explain the somehow contradictory findings regarding several 
AR-regulated biomarkers, such as SOCS or GNMT (409-412). Thus, thorough 
characterization of the dominant transcriptional networks in a given tumour 
might help to improve the accuracy of promising biomarkers and treatment 
stratifiers.
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6. Future perspectives 
 
In Paper I, we identified a compact 33 gene signature that was capable of 
discriminating between BPH, localised PCa and metastatic PCa in several 
publicly available datasets. Since this was a meta-analysis of existing 
datasets, we did not produce any new data from previously uncharacterised 
patients. Naturally, the next step would be to test our signature in a larger 
clinical setting. Various questions could be asked in such a study, e.g. 1) 
does our signature predict the need for a repeat biopsy in case of a negative 
result but elevated PSA levels, analogous to PCA3 (early detection) (386), 2) 
does our signature predict post-operative BCR or metastasis 
(prognostic/recurrence), 3) is it able to distinguish between tissue isolated 
from BPH, primary PCa or metastatic PCa (diagnostic) or 4) if performed on 
biopsy samples, does our signature help to predict treatment efficacy 
(predictive)? A prominent example of an RNA-based gene signature is the 
22 biomarker test GenomeDx Decipher that has recently been tested in a 
range of larger cohorts with so far promising results (381-383). In addition, a 
variety of other diagnostic/prognostic/predictive tests are emerging, e.g. 
Prolaris Myriad and Oncotype DX, which are FDA-approved tools to 
distinguish between indolent and aggressive disease (414). Notably, 
multiple genes in our signature (e.g. ERG, AMACR, CRISP3, GDF15, TDRD1, 
PCA3) have also been applied to assess PCa risk or stratify patients using 
other biological fluids, such as blood or urine (384-386). It will be interesting 
to evaluate the biomarker potential of the remaining genes in our signature 
in these fluids. 
Paper II focused on the de novo purine biosynthesis and identified the IMP-
converting enzyme IMPDH2 as a potential drug target in PCa. However, we 
merely focused on in vitro models in our study (PCa cell lines) and did not 
progress to preclinical models, such as xenografts or transgenic mouse 
models. Thus, a next step would be to assess the efficacy of MPA in 
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xenografted LNCaP or VCaP, preferably in a castrate setting since IMPDH2 
levels in our patient cohorts were elevated in CRPC but not significantly in 
localised disease. Even more intriguing would be transgenic mouse models 
driven by MYC overexpression, such as hiMYC mice (415). Given these 
experiments were to be successful, progression to clinical trials would be an 
option. Since MPA is a clinically approved immunosuppressant (395), initial 
toxicity tests could be omitted and this is a major advantage of drug 
repositioning (Chapter 5). Patient selection should be based on MYC 
expression since this would likely predict the activity of the pathway in the 
patient’s tumour. Strikingly, the current standard of care for CRPC includes a 
combination treatment of an androgen-synthesis inhibitor (Abiraterone) 
with an immunosuppressant (Prednisone) (127, 129). This suggests that 
targeting the immune component of PCa might be beneficial for patients 
and thus MPA could have great potential as a treatment alternative. 
In Paper III we elucidated the antagonistic relationship between MYC and 
the AR. MYC overexpression counteracted androgen-induced gene 
transcription and led to the downregulation of a subset of AR target genes. 
We also validated this antagonistic effect of MYC on the expression of the 
two AR targets KLK3 and GNMT in patient samples using IHC. However, our 
IHC data is merely derived from parallel sections of the same tumour and 
represents an average score. For a more thorough analysis, double-staining 
and more detailed scoring on a cell-by-cell basis would be necessary to 
strengthen the message. Furthermore, making use of novel in situ RNA 
hybridization technologies, such as RNAscope (416), could help to validate 
the antagonistic regulation at the mRNA level. There have been 
contradicting reports regarding the prognostic properties of GNMT 
expression with one study claiming high GNMT levels to be a marker of poor 
outcome (411), and one study showing the opposite (412). Our findings 
suggest that this controversy might actually be explained by the relative 
levels of MYC in the respective tumour samples. Consequently, validation of 
this hypothesis by assessing MYC and GNMT in a larger cohort would be of 
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great interest. Furthermore, our list of MYC antagonised genes contained 
various proteins involved in cellular signalling pathways (e.g. ERRFI1 and 
EGFR signalling, and SOCS2 and JAK/STAT signalling). Her2/EGFR signalling 
is a principal target in breast cancer treatment and targeting this pathway 
has been postulated for the treatment of PCa (417, 418). Similarly, the 
inflammatory JAK/STAT signalling pathway has been shown to play a role in 
PCa and inhibition might be a viable treatment option in the future (419). 
The relative levels of MYC might serve as a surrogate marker for the activity 
of these pathways and concomitantly predict treatment efficacy. 
Overall, this thesis has elucidated the transcriptional role of MYC in PCa and 
unveiled the effects of clinically relevant levels of MYC overexpression on AR 
activity. Further studies will need to assess the translational potential of 
these findings by using better in vivo models and undertaking larger scale 
studies.
   
 
 
  77 
7. References 
 
1. Ford WC, Harrison A. The role of citrate in determining the activity of calcium ions in 
human semen. Int J Androl. 1984;7(3):198-202. 
2. Barfeld SJ, Itkonen HM, Urbanucci A, Mills IG. Androgen-regulated metabolism and 
biosynthesis in prostate cancer. Endocr Relat Cancer. 2014;21(4):T57-66. 
3. Costello LC, Liu Y, Franklin RB, Kennedy MC. Zinc inhibition of mitochondrial aconitase and 
its importance in citrate metabolism of prostate epithelial cells. J Biol Chem. 1997;272(46):28875-81. 
4. Lee CH, Akin-Olugbade O, Kirschenbaum A. Overview of prostate anatomy, histology, and 
pathology. Endocrinol Metab Clin North Am. 2011;40(3):565-75, viii-ix. 
5. School HM. Prostate basics 2011 [cited 2015 19 February]. Available from: 
http://www.harvardprostateknowledge.org/prostate-basics. 
6. So AI, Hurtado-Coll A, Gleave ME. Androgens and prostate cancer. World J Urol. 
2003;21(5):325-37. 
7. Rosner W, Hryb DJ, Khan MS, Nakhla AM, Romas NA. Sex hormone-binding globulin 
mediates steroid hormone signal transduction at the plasma membrane. J Steroid Biochem Mol Biol. 
1999;69(1-6):481-5. 
8. Ruizeveld de Winter JA, Trapman J, Vermey M, Mulder E, Zegers ND, van der Kwast TH. 
Androgen receptor expression in human tissues: an immunohistochemical study. J Histochem 
Cytochem. 1991;39(7):927-36. 
9. Bonkhoff H, Remberger K. Widespread distribution of nuclear androgen receptors in the 
basal cell layer of the normal and hyperplastic human prostate. Virchows Arch A Pathol Anat 
Histopathol. 1993;422(1):35-8. 
10. Veldscholte J, Berrevoets CA, Brinkmann AO, Grootegoed JA, Mulder E. Anti-androgens and 
the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock 
protein interaction, and transcription activation. Biochemistry. 1992;31(8):2393-9. 
11. Brinkmann AO, Blok LJ, de Ruiter PE, Doesburg P, Steketee K, Berrevoets CA, et al. 
Mechanisms of androgen receptor activation and function. J Steroid Biochem Mol Biol. 1999;69(1-
6):307-13. 
12. Nazareth LV, Weigel NL. Activation of the human androgen receptor through a protein 
kinase A signaling pathway. J Biol Chem. 1996;271(33):19900-7. 
13. Chen H, Lin RJ, Schiltz RL, Chakravarti D, Nash A, Nagy L, et al. Nuclear receptor coactivator 
ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and 
CBP/p300. Cell. 1997;90(3):569-80. 
14. Bannister AJ, Kouzarides T. The CBP co-activator is a histone acetyltransferase. Nature. 
1996;384(6610):641-3. 
15. Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y. The transcriptional 
coactivators p300 and CBP are histone acetyltransferases. Cell. 1996;87(5):953-9. 
16. Frønsdal K, Engedal N, Slagsvold T, Saatcioglu F. CREB binding protein is a coactivator for 
the androgen receptor and mediates cross-talk with AP-1. J Biol Chem. 1998;273(48):31853-9. 
17. Kahl P, Gullotti L, Heukamp LC, Wolf S, Friedrichs N, Vorreuther R, et al. Androgen receptor 
coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk 
of prostate cancer recurrence. Cancer Res. 2006;66(23):11341-7. 
18. Hirschhorn JN, Brown SA, Clark CD, Winston F. Evidence that SNF2/SWI2 and SNF5 activate 
transcription in yeast by altering chromatin structure. Genes Dev. 1992;6(12A):2288-98. 
19. Kwon H, Imbalzano AN, Khavari PA, Kingston RE, Green MR. Nucleosome disruption and 
enhancement of activator binding by a human SW1/SNF complex. Nature. 1994;370(6489):477-81. 
20. Marshall TW, Link KA, Petre-Draviam CE, Knudsen KE. Differential requirement of SWI/SNF 
for androgen receptor activity. J Biol Chem. 2003;278(33):30605-13. 
21. Nakajima T, Uchida C, Anderson SF, Lee CG, Hurwitz J, Parvin JD, et al. RNA helicase A 
mediates association of CBP with RNA polymerase II. Cell. 1997;90(6):1107-12. 
22. Shang Y, Myers M, Brown M. Formation of the androgen receptor transcription complex. 
Mol Cell. 2002;9(3):601-10. 
23. Pritchard CC, Nelson PS. Gene expression profiling in the developing prostate. 
Differentiation. 2008;76(6):624-40. 
24. Roberts RO, Jacobsen SJ. Epidemiology of prostatitis. Curr Urol Rep. 2000;1(2):135-41. 
25. Krieger JN, Lee SWH, Jeon J, Cheah PY, Liong ML, Riley DE. Epidemiology of prostatitis. Int J 
Antimicrob Agents. 2008;31 Suppl 1:S85-90. 
References 
 78 
26. Lipsky BA, Byren I, Hoey CT. Treatment of bacterial prostatitis. Clin Infect Dis. 
2010;50(12):1641-52. 
27. Sfanos KS, Isaacs WB, De Marzo AM. Infections and inflammation in prostate cancer. Am J 
Clin Exp Urol. 2013;1(1):3-11. 
28. Krieger JN, Nyberg L, Nickel JC. NIH consensus definition and classification of prostatitis. 
JAMA. 1999;282(3):236-7. 
29. Woenckhaus J, Fenic I. Proliferative inflammatory atrophy: a background lesion of prostate 
cancer? Andrologia. 2008;40(2):134-7. 
30. Dennis LK, Lynch CF, Torner JC. Epidemiologic association between prostatitis and prostate 
cancer. Urology. 2002;60(1):78-83. 
31. Jiang J, Li J, Yunxia Z, Zhu H, Liu J, Pumill C. The role of prostatitis in prostate cancer: meta-
analysis. PLoS One. 2013;8(12):e85179. 
32. Khalili M, Mutton LN, Gurel B, Hicks JL, De Marzo AM, Bieberich CJ. Loss of Nkx3.1 
expression in bacterial prostatitis: a potential link between inflammation and neoplasia. Am J Pathol. 
2010;176(5):2259-68. 
33. Simons BD, Morrison AS, Young RH, Verhoek-Oftedahl W. The relation of surgery for 
prostatic hypertrophy to carcinoma of the prostate. Am J Epidemiol. 1993;138(5):294-300. 
34. Ørsted DD, Bojesen SE, Nielsen SF, Nordestgaard BG. Association of clinical benign prostate 
hyperplasia with prostate cancer incidence and mortality revisited: a nationwide cohort study of 
3,009,258 men. Eur Urol. 2011;60(4):691-8. 
35. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57-70. 
36. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-
74. 
37. De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the 
prostate: implications for prostatic carcinogenesis. Am J Pathol. 1999;155(6):1985-92. 
38. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG, et al. Inflammation in 
prostate carcinogenesis. Nat Rev Cancer. 2007;7(4):256-69. 
39. Ruska KM, Sauvageot J, Epstein JI. Histology and cellular kinetics of prostatic atrophy. Am J 
Surg Pathol. 1998;22(9):1073-7. 
40. Choo-Kang BSW, Hutchison S, Nickdel MB, Bundick RV, Leishman AJ, Brewer JM, et al. TNF-
blocking therapies: an alternative mode of action? Trends Immunol. 2005;26(10):518-22. 
41. Malaviya R, Ikeda T, Ross E, Abraham SN. Mast cell modulation of neutrophil influx and 
bacterial clearance at sites of infection through TNF-alpha. Nature. 1996;381(6577):77-80. 
42. Bostwick DG, Qian J. High-grade prostatic intraepithelial neoplasia. Mod Pathol. 
2004;17(3):360-79. 
43. Montironi R, Mazzucchelli R, Lopez-Beltran A, Cheng L, Scarpelli M. Mechanisms of disease: 
high-grade prostatic intraepithelial neoplasia and other proposed preneoplastic lesions in the prostate. 
Nat Clin Pract Urol. 2007;4(6):321-32. 
44. Davidson D, Bostwick DG, Qian J, Wollan PC, Oesterling JE, Rudders RA, et al. Prostatic 
intraepithelial neoplasia is a risk factor for adenocarcinoma: predictive accuracy in needle biopsies. J 
Urol. 1995;154(4):1295-9. 
45. DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI. Pathological and molecular aspects of 
prostate cancer. Lancet. 2003;361(9361):955-64. 
46. Gokden N, Roehl KA, Catalona WJ, Humphrey PA. High-grade prostatic intraepithelial 
neoplasia in needle biopsy as risk factor for detection of adenocarcinoma: current level of risk in 
screening population. Urology. 2005;65(3):538-42. 
47. Herawi M, Kahane H, Cavallo C, Epstein JI. Risk of prostate cancer on first re-biopsy within 1 
year following a diagnosis of high grade prostatic intraepithelial neoplasia is related to the number of 
cores sampled. J Urol. 2006;175(1):121-4. 
48. School HM. What is prostatic intraepithelial neoplasia (PIN)? 2007 [cited 2015 1 July]. 
Available from: http://www.harvardprostateknowledge.org/what-is-prostatic-intraepithelial-neoplasia-
pin. 
49. Bubendorf L, Schöpfer A, Wagner U, Sauter G, Moch H, Willi N, et al. Metastatic patterns of 
prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 2000;31(5):578-83. 
50. Wang ZA, Toivanen R, Bergren SK, Chambon P, Shen MM. Luminal cells are favored as the 
cell of origin for prostate cancer. Cell Rep. 2014;8(5):1339-46. 
51. Goldstein AS, Lawson DA, Cheng D, Sun W, Garraway IP, Witte ON. Trop2 identifies a 
subpopulation of murine and human prostate basal cells with stem cell characteristics. Proc Natl Acad 
Sci U S A. 2008;105(52):20882-7. 
52. Goldstein AS, Huang J, Guo C, Garraway IP, Witte ON. Identification of a cell of origin for 
human prostate cancer. Science. 2010;329(5991):568-71. 
53. Wang X, Kruithof-de Julio M, Economides KD, Walker D, Yu H, Halili MV, et al. A luminal 
epithelial stem cell that is a cell of origin for prostate cancer. Nature. 2009;461(7263):495-500. 
References 
 
 
79 
54. Stoyanova T, Cooper AR, Drake JM, Liu X, Armstrong AJ, Pienta KJ, et al. Prostate cancer 
originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells. Proc Natl 
Acad Sci U S A. 2013;110(50):20111-6. 
55. Brawley OW. Prostate cancer epidemiology in the United States. World J Urol. 
2012;30(2):195-200. 
56. cancer.org. Prostate cancer key statistics 2015 [cited 2015 19 February]. Available from: 
http://www.cancer.org/cancer/prostatecancer/detailedguide/prostate-cancer-key-statistics. 
57. kreftregisteret. Fakta om prostatakreft 2014 [cited 2015 19 February]. Available from: 
http://kreftregisteret.no/no/Generelt/Fakta-om-kreft-test/Prostatakreft/. 
58. Cancer IAfRo. Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012 
2014 [cited 2015 19 February]. Available from: http://globocan.iarc.fr/Default.aspx. 
59. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International 
variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61(6):1079-92. 
60. Salinas CA, Tsodikov A, Ishak-Howard M, Cooney KA. Prostate cancer in young men: an 
important clinical entity. Nat Rev Urol. 2014;11(6):317-23. 
61. Network NCI. Cancer Incidence and Survival by Major Ethnic Group 2009. Available from: 
http://www.ncin.org.uk/. 
62. Institute NC. SEER Incidence and Mortality trends 2000-2009 2010 [cited 2015 26 February]. 
Available from: http://seer.cancer.gov/archive/csr/1975_2009_pops09/. 
63. Hoffman RM, Gilliland FD, Eley JW, Harlan LC, Stephenson RA, Stanford JL, et al. Racial and 
ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. J Natl 
Cancer Inst. 2001;93(5):388-95. 
64. MacInnis RJ, English DR. Body size and composition and prostate cancer risk: systematic 
review and meta-regression analysis. Cancer Causes Control. 2006;17(8):989-1003. 
65. Discacciati A, Orsini N, Wolk A. Body mass index and incidence of localized and advanced 
prostate cancer--a dose-response meta-analysis of prospective studies. Ann Oncol. 2012;23(7):1665-71. 
66. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth 
factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. 
Lancet. 2004;363(9418):1346-53. 
67. Roddam AW, Allen NE, Appleby P, Key TJ, Ferrucci L, Carter HB, et al. Insulin-like growth 
factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 
prospective studies. Ann Intern Med. 2008;149(7):461-71, W83-8. 
68. Johns LE, Houlston RS. A systematic review and meta-analysis of familial prostate cancer 
risk. BJU Int. 2003;91(9):789-94. 
69. Bruner DW, Moore D, Parlanti A, Dorgan J, Engstrom P. Relative risk of prostate cancer for 
men with affected relatives: systematic review and meta-analysis. Int J Cancer. 2003;107(5):797-803. 
70. Lange EM, Salinas CA, Zuhlke KA, Ray AM, Wang Y, Lu Y, et al. Early onset prostate cancer 
has a significant genetic component. Prostate. 2012;72(2):147-56. 
71. Xu J, Meyers D, Freije D, Isaacs S, Wiley K, Nusskern D, et al. Evidence for a prostate cancer 
susceptibility locus on the X chromosome. Nat Genet. 1998;20(2):175-9. 
72. Amundadottir LT, Sulem P, Gudmundsson J, Helgason A, Baker A, Agnarsson BA, et al. A 
common variant associated with prostate cancer in European and African populations. Nat Genet. 
2006;38(6):652-8. 
73. Eeles RA, Kote-Jarai Z, Giles GG, Olama AAA, Guy M, Jugurnauth SK, et al. Multiple newly 
identified loci associated with prostate cancer susceptibility. Nat Genet. 2008;40(3):316-21. 
74. Thomas G, Jacobs KB, Yeager M, Kraft P, Wacholder S, Orr N, et al. Multiple loci identified in 
a genome-wide association study of prostate cancer. Nat Genet. 2008;40(3):310-5. 
75. Mills IG. HOXB13, RFX6 and prostate cancer risk. Nat Genet. 2014;46(2):94-5. 
76. Huang Q, Whitington T, Gao P, Lindberg JF, Yang Y, Sun J, et al. A prostate cancer 
susceptibility allele at 6q22 increases RFX6 expression by modulating HOXB13 chromatin binding. Nat 
Genet. 2014;46(2):126-35. 
77. Ewing CM, Ray AM, Lange EM, Zuhlke KA, Robbins CM, Tembe WD, et al. Germline 
mutations in HOXB13 and prostate-cancer risk. N Engl J Med. 2012;366(2):141-9. 
78. Xu J, Lange EM, Lu L, Zheng SL, Wang Z, Thibodeau SN, et al. HOXB13 is a susceptibility 
gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics 
(ICPCG). Hum Genet. 2013;132(1):5-14. 
79. Consortium BCL. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst. 
1999;91(15):1310-6. 
80. Hemminki K, Czene K. Age specific and attributable risks of familial prostate carcinoma 
from the family-cancer database. Cancer. 2002;95(6):1346-53. 
81. Gao X, LaValley MP, Tucker KL. Prospective studies of dairy product and calcium intakes 
and prostate cancer risk: a meta-analysis. J Natl Cancer Inst. 2005;97(23):1768-77. 
References 
 80 
82. Huncharek M, Muscat J, Kupelnick B. Dairy products, dietary calcium and vitamin D intake 
as risk factors for prostate cancer: a meta-analysis of 26,769 cases from 45 observational studies. Nutr 
Cancer. 2008;60(4):421-41. 
83. Collin SM, Metcalfe C, Refsum H, Lewis SJ, Zuccolo L, Smith GD, et al. Circulating folate, 
vitamin B12, homocysteine, vitamin B12 transport proteins, and risk of prostate cancer: a case-control 
study, systematic review, and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2010;19(6):1632-42. 
84. Wien TN, Pike E, Wisløff T, Staff A, Smeland S, Klemp M. Cancer risk with folic acid 
supplements: a systematic review and meta-analysis. BMJ Open. 2012;2(1):e000653. 
85. Julin B, Wolk A, Johansson J-E, Andersson S-O, Andrén O, Akesson A. Dietary cadmium 
exposure and prostate cancer incidence: a population-based prospective cohort study. Br J Cancer. 
2012;107(5):895-900. 
86. Van Maele-Fabry G, Willems JL. Occupation related pesticide exposure and cancer of the 
prostate: a meta-analysis. Occup Environ Med. 2003;60(9):634-42. 
87. Van Maele-Fabry G, Willems JL. Prostate cancer among pesticide applicators: a meta-
analysis. Int Arch Occup Environ Health. 2004;77(8):559-70. 
88. Van Maele-Fabry G, Libotte V, Willems J, Lison D. Review and meta-analysis of risk estimates 
for prostate cancer in pesticide manufacturing workers. Cancer Causes Control. 2006;17(4):353-73. 
89. Ilic D, Misso M. Lycopene for the prevention and treatment of benign prostatic hyperplasia 
and prostate cancer: a systematic review. Maturitas. 2012;72(4):269-76. 
90. Etminan M, Takkouche B, Caamaño-Isorna F. The role of tomato products and lycopene in 
the prevention of prostate cancer: a meta-analysis of observational studies. Cancer Epidemiol 
Biomarkers Prev. 2004;13(3):340-5. 
91. Hurst R, Hooper L, Norat T, Lau R, Aune D, Greenwood DC, et al. Selenium and prostate 
cancer: systematic review and meta-analysis. Am J Clin Nutr. 2012;96(1):111-22. 
92. Dennert G, Zwahlen M, Brinkman M, Vinceti M, Zeegers MPA, Horneber M. Selenium for 
preventing cancer. Cochrane Database Syst Rev. 2011(5):CD005195. 
93. UK CR. Prostate Cancer Risk Factors 2014. Available from: 
http://www.cancerresearchuk.org/cancer-info/cancerstats/types/prostate/riskfactors/prostate-cancer-
risk-factors. 
94. Cogliano VJ, Baan R, Straif K, Grosse Y, Lauby-Secretan B, El Ghissassi F, et al. Preventable 
exposures associated with human cancers. J Natl Cancer Inst. 2011;103(24):1827-39. 
95. Miller DC, Hafez KS, Stewart A, Montie JE, Wei JT. Prostate carcinoma presentation, 
diagnosis, and staging: an update form the National Cancer Data Base. Cancer. 2003;98(6):1169-78. 
96. Karantanos T, Evans CP, Tombal B, Thompson TC, Montironi R, Isaacs WB. Understanding 
the Mechanisms of Androgen Deprivation Resistance in Prostate Cancer at the Molecular Level. Eur 
Urol. 2014. 
97. Cheng L, Montironi R, Bostwick DG, Lopez-Beltran A, Berney DM. Staging of prostate 
cancer. Histopathology. 2012;60(1):87-117. 
98. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the 
AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471-4. 
99. Malm J, Hellman J, Hogg P, Lilja H. Enzymatic action of prostate-specific antigen (PSA or 
hK3): substrate specificity and regulation by Zn(2+), a tight-binding inhibitor. Prostate. 2000;45(2):132-
9. 
100. Lilja H, Oldbring J, Rannevik G, Laurell CB. Seminal vesicle-secreted proteins and their 
reactions during gelation and liquefaction of human semen. J Clin Invest. 1987;80(2):281-5. 
101. Robert M, Gibbs BF, Jacobson E, Gagnon C. Characterization of prostate-specific antigen 
proteolytic activity on its major physiological substrate, the sperm motility inhibitor 
precursor/semenogelin I. Biochemistry. 1997;36(13):3811-9. 
102. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, et al. Serum 
prostate-specific antigen in a community-based population of healthy men. Establishment of age-
specific reference ranges. JAMA. 1993;270(7):860-4. 
103. DeAntoni EP, Crawford ED, Oesterling JE, Ross CA, Berger ER, McLeod DG, et al. Age- and 
race-specific reference ranges for prostate-specific antigen from a large community-based study. 
Urology. 1996;48(2):234-9. 
104. Balk SP, Ko Y-J, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol. 2003;21(2):383-
91. 
105. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence 
of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J 
Med. 2004;350(22):2239-46. 
106. Crawford ED, Schutz MJ, Clejan S, Drago J, Resnick MI, Chodak GW, et al. The effect of 
digital rectal examination on prostate-specific antigen levels. JAMA. 1992;267(16):2227-8. 
107. Chybowski FM, Bergstralh EJ, Oesterling JE. The effect of digital rectal examination on the 
serum prostate specific antigen concentration: results of a randomized study. J Urol. 1992;148(1):83-6. 
References 
 
 
81 
108. Bañez LL, Hamilton RJ, Partin AW, Vollmer RT, Sun L, Rodriguez C, et al. Obesity-related 
plasma hemodilution and PSA concentration among men with prostate cancer. JAMA. 
2007;298(19):2275-80. 
109. Djulbegovic M, Beyth RJ, Neuberger MM, Stoffs TL, Vieweg J, Djulbegovic B, et al. Screening 
for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ. 
2010;341:c4543. 
110. Brimo F, Montironi R, Egevad L, Erbersdobler A, Lin DW, Nelson JB, et al. Contemporary 
grading for prostate cancer: implications for patient care. Eur Urol. 2013;63(5):892-901. 
111. Epstein JI, Allsbrook WC, Amin MB, Egevad LL, Committee IG. The 2005 International 
Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic 
Carcinoma. Am J Surg Pathol. 2005;29(9):1228-42. 
112. Epstein JI. An update of the Gleason grading system. J Urol. 2010;183(2):433-40. 
113. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by 
combined histological grading and clinical staging. J Urol. 1974;111(1):58-64. 
114. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen M-H. Cancer-specific mortality after 
surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-
specific antigen era. J Clin Oncol. 2003;21(11):2163-72. 
115. Cooperberg MR, Pasta DJ, Elkin EP, Litwin MS, Latini DM, Du Chane J, et al. The University of 
California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable 
preoperative predictor of disease recurrence after radical prostatectomy. J Urol. 2005;173(6):1938-42. 
116. Society AC. Prostate cancer treatment 2015 [cited 2015 23 February]. Available from: 
http://www.cancer.org/cancer/prostatecancer/detailedguide/prostate-cancer-treating-general-info. 
117. Society AC. Survival rates for prostate cancer 2015 [cited 2015 23 February]. Available from: 
http://www.cancer.org/cancer/prostatecancer/detailedguide/prostate-cancer-survival-rates. 
118. UK CR. Statistics and outlook for prostate cancer 2015 [cited 2015 23 February]. Available 
from: http://www.cancerresearchuk.org/about-cancer/type/prostate-cancer/treatment/statistics-and-
outlook-for-prostate-cancer#stage1. 
119. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of 
progression after PSA elevation following radical prostatectomy. JAMA. 1999;281(17):1591-7. 
120. Roehl KA, Han M, Ramos CG, Antenor JAV, Catalona WJ. Cancer progression and survival 
rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term 
results. J Urol. 2004;172(3):910-4. 
121. Bruce JY, Lang JM, McNeel DG, Liu G. Current controversies in the management of 
biochemical failure in prostate cancer. Clin Adv Hematol Oncol. 2012;10(11):716-22. 
122. Studer UE, Whelan P, Albrecht W, Casselman J, de Reijke T, Hauri D, et al. Immediate or 
deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with 
curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin 
Oncol. 2006;24(12):1868-76. 
123. Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, et al. Immediate versus 
deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical 
prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006;7(6):472-9. 
124. Studer UE, Hauri D, Hanselmann S, Chollet D, Leisinger H-J, Gasser T, et al. Immediate 
versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative 
local treatment: results of the randomized trial SAKK 08/88. J Clin Oncol. 2004;22(20):4109-18. 
125. Prezioso D, Iacono F, Romeo G, Ruffo A, Russo N, Illiano E. Early versus delayed hormonal 
treatment in locally advanced or asymptomatic metastatic prostatic cancer patient dilemma. World J 
Urol. 2014;32(3):661-7. 
126. Lipton A. Implications of bone metastases and the benefits of bone-targeted therapy. 
Semin Oncol. 2010;37 Suppl 2:S15-29. 
127. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU 
guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant 
prostate cancer. Eur Urol. 2014;65(2):467-79. 
128. Wu JN, Fish KM, Evans CP, Devere White RW, Dall'Era MA. No improvement noted in overall 
or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period. 
Cancer. 2014;120(6):818-23. 
129. Association AU. Castration-resistant Prostate Cancer: AUA Guideline 2014 [cited 2015 23 
February]. Available from: https://www.auanet.org/education/guidelines/castration-resistant-prostate-
cancer.cfm. 
130. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. Long-term 
efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic 
hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96(11):879-82. 
131. Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, et al. Alpha emitter radium-
223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213-23. 
References 
 82 
132. Attard G, Sydes MR, Mason MD, Clarke NW, Aebersold D, de Bono JS, et al. Combining 
enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial. 
Eur Urol. 2014;66(5):799-802. 
133. James ND, Spears MR, Clarke NW, Dearnaley DP, De Bono JS, Gale J, et al. Survival with 
Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the 
Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). Eur Urol. 2015;67(6):1028-38. 
134. Huggins C. EFFECT OF ORCHIECTOMY AND IRRADIATION ON CANCER OF THE PROSTATE. 
Ann Surg. 1942;115(6):1192-200. 
135. Denmeade SR, Isaacs JT. A history of prostate cancer treatment. Nat Rev Cancer. 
2002;2(5):389-96. 
136. Mainwaring WI. A soluble androgen receptor in the cytoplasm of rat prostate. J Endocrinol. 
1969;45(4):531-41. 
137. Bruchovsky N, Wilson JD. The intranuclear binding of testosterone and 5-alpha-androstan-
17-beta-ol-3-one by rat prostate. J Biol Chem. 1968;243(22):5953-60. 
138. Anderson KM, Liao S. Selective retention of dihydrotestosterone by prostatic nuclei. 
Nature. 1968;219(5151):277-9. 
139. Shen MM, Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old 
challenges. Genes Dev. 2010;24(18):1967-2000. 
140. Bowen C, Stuart A, Ju J-H, Tuan J, Blonder J, Conrads TP, et al. NKX3.1 homeodomain 
protein binds to topoisomerase I and enhances its activity. Cancer Res. 2007;67(2):455-64. 
141. Haffner MC, Aryee MJ, Toubaji A, Esopi DM, Albadine R, Gurel B, et al. Androgen-induced 
TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet. 
2010;42(8):668-75. 
142. Haffner MC, De Marzo AM, Meeker AK, Nelson WG, Yegnasubramanian S. Transcription-
induced DNA double strand breaks: both oncogenic force and potential therapeutic target? Clin Cancer 
Res. 2011;17(12):3858-64. 
143. Felsher DW, Bishop JM. Transient excess of MYC activity can elicit genomic instability and 
tumorigenesis. Proc Natl Acad Sci U S A. 1999;96(7):3940-4. 
144. Mills IG. Maintaining and reprogramming genomic androgen receptor activity in prostate 
cancer. Nat Rev Cancer. 2014;14(3):187-98. 
145. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, et al. 
Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-
resistant tumor growth. Cancer Res. 2008;68(11):4447-54. 
146. Tilley WD, Buchanan G, Hickey TE, Bentel JM. Mutations in the androgen receptor gene are 
associated with progression of human prostate cancer to androgen independence. Clin Cancer Res. 
1996;2(2):277-85. 
147. Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J, et al. Androgen receptor 
gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in 
prostate cancer. Cancer Res. 1997;57(2):314-9. 
148. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, et al. Ligand-independent 
androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate 
cancer. Cancer Res. 2009;69(1):16-22. 
149. Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: 
progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin 
Pract Urol. 2009;6(2):76-85. 
150. Mohler JL, Titus MA, Bai S, Kennerley BJ, Lih FB, Tomer KB, et al. Activation of the androgen 
receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer. 
Cancer Res. 2011;71(4):1486-96. 
151. Cooper CS, Eeles R, Wedge DC, Van Loo P, Gundem G, Alexandrov LB, et al. Analysis of the 
genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in 
neoplastic and morphologically normal prostate tissue. Nat Genet. 2015. 
152. Aihara M, Wheeler TM, Ohori M, Scardino PT. Heterogeneity of prostate cancer in radical 
prostatectomy specimens. Urology. 1994;43(1):60-6; discussion 6-7. 
153. Arora R, Koch MO, Eble JN, Ulbright TM, Li L, Cheng L. Heterogeneity of Gleason grade in 
multifocal adenocarcinoma of the prostate. Cancer. 2004;100(11):2362-6. 
154. Cheng L, Song SY, Pretlow TG, Abdul-Karim FW, Kung HJ, Dawson DV, et al. Evidence of 
independent origin of multiple tumors from patients with prostate cancer. J Natl Cancer Inst. 
1998;90(3):233-7. 
155. Villers A, McNeal JE, Freiha FS, Stamey TA. Multiple cancers in the prostate. Morphologic 
features of clinically recognized versus incidental tumors. Cancer. 1992;70(9):2313-8. 
156. Lindberg J, Klevebring D, Liu W, Neiman M, Xu J, Wiklund P, et al. Exome sequencing of 
prostate cancer supports the hypothesis of independent tumour origins. Eur Urol. 2013;63(2):347-53. 
References 
 
 
83 
157. Andreoiu M, Cheng L. Multifocal prostate cancer: biologic, prognostic, and therapeutic 
implications. Hum Pathol. 2010;41(6):781-93. 
158. Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, Yu G, et al. Copy number analysis indicates 
monoclonal origin of lethal metastatic prostate cancer. Nat Med. 2009;15(5):559-65. 
159. Lindberg J, Kristiansen A, Wiklund P, Grönberg H, Egevad L. Tracking the origin of 
metastatic prostate cancer. Eur Urol. 2015;67(5):819-22. 
160. Haffner MC, Mosbruger T, Esopi DM, Fedor H, Heaphy CM, Walker DA, et al. Tracking the 
clonal origin of lethal prostate cancer. J Clin Invest. 2013;123(11):4918-22. 
161. Barbieri CE, Bangma CH, Bjartell A, Catto JWF, Culig Z, Grönberg H, et al. The mutational 
landscape of prostate cancer. Eur Urol. 2013;64(4):567-76. 
162. Spans L, Clinckemalie L, Helsen C, Vanderschueren D, Boonen S, Lerut E, et al. The genomic 
landscape of prostate cancer. Int J Mol Sci. 2013;14(6):10822-51. 
163. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, et al. Mutational landscape and 
significance across 12 major cancer types. Nature. 2013;502(7471):333-9. 
164. Robinson D, Van Allen EM, Wu Y-M, Schultz N, Lonigro RJ, Mosquera J-M, et al. Integrative 
clinical genomics of advanced prostate cancer. Cell. 2015;161(5):1215-28. 
165. Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat J-P, et al. Exome 
sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet. 
2012;44(6):685-9. 
166. Grasso CS, Wu Y-M, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational 
landscape of lethal castration-resistant prostate cancer. Nature. 2012;487(7406):239-43. 
167. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic 
profiling of human prostate cancer. Cancer Cell. 2010;18(1):11-22. 
168. Beltran H, Yelensky R, Frampton GM, Park K, Downing SR, MacDonald TY, et al. Targeted 
next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and 
disease heterogeneity. Eur Urol. 2013;63(5):920-6. 
169. Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman JG, et al. Frequent 
inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res. 1997;57(22):4997-5000. 
170. Boormans JL, Hermans KG, van Leenders GJLH, Trapman J, Verhagen PCMS. An activating 
mutation in AKT1 in human prostate cancer. Int J Cancer. 2008;123(11):2725-6. 
171. Sun X, Huang J, Homma T, Kita D, Klocker H, Schafer G, et al. Genetic alterations in the PI3K 
pathway in prostate cancer. Anticancer Res. 2009;29(5):1739-43. 
172. Gioeli D, Mandell JW, Petroni GR, Frierson HF, Weber MJ. Activation of mitogen-activated 
protein kinase associated with prostate cancer progression. Cancer Res. 1999;59(2):279-84. 
173. Paweletz CP, Charboneau L, Bichsel VE, Simone NL, Chen T, Gillespie JW, et al. Reverse 
phase protein microarrays which capture disease progression show activation of pro-survival pathways 
at the cancer invasion front. Oncogene. 2001;20(16):1981-9. 
174. Malik SN, Brattain M, Ghosh PM, Troyer DA, Prihoda T, Bedolla R, et al. 
Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin 
Cancer Res. 2002;8(4):1168-71. 
175. Cooney KA, Wetzel JC, Merajver SD, Macoska JA, Singleton TP, Wojno KJ. Distinct regions of 
allelic loss on 13q in prostate cancer. Cancer Res. 1996;56(5):1142-5. 
176. Melamed J, Einhorn JM, Ittmann MM. Allelic loss on chromosome 13q in human prostate 
carcinoma. Clin Cancer Res. 1997;3(10):1867-72. 
177. Latil A, Bièche I, Pesche S, Volant A, Valèri A, Fournier G, et al. Loss of heterozygosity at 
chromosome arm 13q and RB1 status in human prostate cancer. Hum Pathol. 1999;30(7):809-15. 
178. Lu W, Takahashi H, Furusato M, Maekawa S, Nakano M, Meng C, et al. Allelotyping analysis 
at chromosome 13q of high-grade prostatic intraepithelial neoplasia and clinically insignificant and 
significant prostate cancers. Prostate. 2006;66(4):405-12. 
179. Kibel AS, Faith DA, Bova GS, Isaacs WB. Loss of heterozygosity at 12P12-13 in primary and 
metastatic prostate adenocarcinoma. J Urol. 2000;164(1):192-6. 
180. Kumar A, White TA, MacKenzie AP, Clegg N, Lee C, Dumpit RF, et al. Exome sequencing 
identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc Natl Acad 
Sci U S A. 2011;108(41):17087-92. 
181. Lindberg J, Mills IG, Klevebring D, Liu W, Neiman M, Xu J, et al. The mitochondrial and 
autosomal mutation landscapes of prostate cancer. Eur Urol. 2013;63(4):702-8. 
182. Fan K, Dao DD, Schutz M, Fink LM. Loss of heterozygosity and overexpression of p53 gene 
in human primary prostatic adenocarcinoma. Diagn Mol Pathol. 1994;3(4):265-70. 
183. Jenkins RB, Qian J, Lieber MM, Bostwick DG. Detection of c-myc oncogene amplification 
and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. 
Cancer Res. 1997;57(3):524-31. 
References 
 84 
184. Sato K, Qian J, Slezak JM, Lieber MM, Bostwick DG, Bergstralh EJ, et al. Clinical significance 
of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. J Natl 
Cancer Inst. 1999;91(18):1574-80. 
185. Fleming WH, Hamel A, MacDonald R, Ramsey E, Pettigrew NM, Johnston B, et al. Expression 
of the c-myc protooncogene in human prostatic carcinoma and benign prostatic hyperplasia. Cancer 
Res. 1986;46(3):1535-8. 
186. Gurel B, Iwata T, Koh CM, Jenkins RB, Lan F, Van Dang C, et al. Nuclear MYC protein 
overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol. 2008;21(9):1156-
67. 
187. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinänen R, Palmberg C, et al. In vivo 
amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet. 
1995;9(4):401-6. 
188. Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, et al. Distinct 
transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its 
splice variants in castration-resistant prostate cancer. Cancer Res. 2012;72(14):3457-62. 
189. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun X-W, et al. Recurrent 
fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310(5748):644-
8. 
190. Cerveira N, Ribeiro FR, Peixoto A, Costa V, Henrique R, Jerónimo C, et al. TMPRSS2-ERG gene 
fusion causing ERG overexpression precedes chromosome copy number changes in prostate 
carcinomas and paired HGPIN lesions. Neoplasia. 2006;8(10):826-32. 
191. Perner S, Mosquera J-M, Demichelis F, Hofer MD, Paris PL, Simko J, et al. TMPRSS2-ERG 
fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol. 
2007;31(6):882-8. 
192. Mosquera J-M, Perner S, Genega EM, Sanda M, Hofer MD, Mertz KD, et al. Characterization 
of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical 
implications. Clin Cancer Res. 2008;14(11):3380-5. 
193. Bethel CR, Faith D, Li X, Guan B, Hicks JL, Lan F, et al. Decreased NKX3.1 protein expression 
in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with 
gleason score and chromosome 8p deletion. Cancer Res. 2006;66(22):10683-90. 
194. Asatiani E, Huang W-X, Wang A, Rodriguez Ortner E, Cavalli LR, Haddad BR, et al. Deletion, 
methylation, and expression of the NKX3.1 suppressor gene in primary human prostate cancer. Cancer 
Res. 2005;65(4):1164-73. 
195. Bowen C, Bubendorf L, Voeller HJ, Slack R, Willi N, Sauter G, et al. Loss of NKX3.1 expression 
in human prostate cancers correlates with tumor progression. Cancer Res. 2000;60(21):6111-5. 
196. Liu W, Lindberg J, Sui G, Luo J, Egevad L, Li T, et al. Identification of novel CHD1-associated 
collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer. 
Oncogene. 2012;31(35):3939-48. 
197. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, et al. The 
genomic complexity of primary human prostate cancer. Nature. 2011;470(7333):214-20. 
198. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, et al. The 
polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 
2002;419(6907):624-9. 
199. Saramäki OR, Tammela TLJ, Martikainen PM, Vessella RL, Visakorpi T. The gene for 
polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer. 
Genes Chromosomes Cancer. 2006;45(7):639-45. 
200. Nakayama M, Bennett CJ, Hicks JL, Epstein JI, Platz EA, Nelson WG, et al. Hypermethylation 
of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of 
proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: 
a detailed study using laser-capture microdissection. Am J Pathol. 2003;163(3):923-33. 
201. Yu J, Yu J, Mani R-S, Cao Q, Brenner CJ, Cao X, et al. An integrated network of androgen 
receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell. 
2010;17(5):443-54. 
202. Massie CE, Lynch A, Ramos-Montoya A, Boren J, Stark R, Fazli L, et al. The androgen 
receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J. 
2011;30(13):2719-33. 
203. Sharma NL, Massie CE, Ramos-Montoya A, Zecchini V, Scott HE, Lamb AD, et al. The 
androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in 
man. Cancer Cell. 2013;23(1):35-47. 
204. Bonaccorsi L, Nosi D, Muratori M, Formigli L, Forti G, Baldi E. Altered endocytosis of 
epidermal growth factor receptor in androgen receptor positive prostate cancer cell lines. J Mol 
Endocrinol. 2007;38(1-2):51-66. 
References 
 
 
85 
205. Engelman JA, Cantley LC. A sweet new role for EGFR in cancer. Cancer Cell. 2008;13(5):375-
6. 
206. Traish AM, Morgentaler A. Epidermal growth factor receptor expression escapes androgen 
regulation in prostate cancer: a potential molecular switch for tumour growth. Br J Cancer. 
2009;101(12):1949-56. 
207. Helgeson BE, Tomlins SA, Shah N, Laxman B, Cao Q, Prensner JR, et al. Characterization of 
TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res. 2008;68(1):73-80. 
208. Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS, et al. Distinct 
classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature. 
2007;448(7153):595-9. 
209. Nam RK, Sugar L, Yang W, Srivastava S, Klotz LH, Yang L-Y, et al. Expression of the 
TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J 
Cancer. 2007;97(12):1690-5. 
210. Wang J, Cai Y, Ren C, Ittmann M. Expression of variant TMPRSS2/ERG fusion messenger 
RNAs is associated with aggressive prostate cancer. Cancer Res. 2006;66(17):8347-51. 
211. Dal Pra A, Lalonde E, Sykes J, Warde F, Ishkanian A, Meng A, et al. TMPRSS2-ERG status is 
not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair. 
Clin Cancer Res. 2013;19(18):5202-9. 
212. Gopalan A, Leversha MA, Satagopan JM, Zhou Q, Al-Ahmadie HA, Fine SW, et al. TMPRSS2-
ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res. 
2009;69(4):1400-6. 
213. Hermans KG, Boormans JL, Gasi D, van Leenders GJHL, Jenster G, Verhagen PCMS, et al. 
Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with 
favorable prognosis of prostate cancer. Clin Cancer Res. 2009;15(20):6398-403. 
214. Saramäki OR, Harjula AE, Martikainen PM, Vessella RL, Tammela TLJ, Visakorpi T. 
TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer 
Res. 2008;14(11):3395-400. 
215. Mounir Z, Lin F, Lin VG, Korn JM, Yu Y, Valdez R, et al. TMPRSS2:ERG blocks neuroendocrine 
and luminal cell differentiation to maintain prostate cancer proliferation. Oncogene. 2014. 
216. Sun C, Dobi A, Mohamed A, Li H, Thangapazham RL, Furusato B, et al. TMPRSS2-ERG fusion, 
a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial 
differentiation. Oncogene. 2008;27(40):5348-53. 
217. Baena E, Shao Z, Linn DE, Glass K, Hamblen MJ, Fujiwara Y, et al. ETV1 directs androgen 
metabolism and confers aggressive prostate cancer in targeted mice and patients. Genes Dev. 
2013;27(6):683-98. 
218. Chen Y, Chi P, Rockowitz S, Iaquinta PJ, Shamu T, Shukla S, et al. ETS factors reprogram the 
androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. Nat Med. 
2013;19(8):1023-9. 
219. Higgins J, Brogley M, Palanisamy N, Mehra R, Ittmann MM, Li JZ, et al. Interaction of the 
Androgen Receptor, ETV1, and PTEN Pathways in Mouse Prostate Varies with Pathological Stage and 
Predicts Cancer Progression. Horm Cancer. 2015. 
220. Sharma NL, Massie CE, Butter F, Mann M, Bon H, Ramos-Montoya A, et al. The ETS family 
member GABPα modulates androgen receptor signalling and mediates an aggressive phenotype in 
prostate cancer. Nucleic Acids Res. 2014;42(10):6256-69. 
221. King JC, Xu J, Wongvipat J, Hieronymus H, Carver BS, Leung DH, et al. Cooperativity of 
TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet. 2009;41(5):524-6. 
222. Thangapazham R, Saenz F, Katta S, Mohamed AA, Tan S-H, Petrovics G, et al. Loss of the 
NKX3.1 tumorsuppressor promotes the TMPRSS2-ERG fusion gene expression in prostate cancer. BMC 
Cancer. 2014;14:16. 
223. Lehmann OJ, Sowden JC, Carlsson P, Jordan T, Bhattacharya SS. Fox's in development and 
disease. Trends Genet. 2003;19(6):339-44. 
224. Zhao Y, Tindall DJ, Huang H. Modulation of androgen receptor by FOXA1 and FOXO1 
factors in prostate cancer. Int J Biol Sci. 2014;10(6):614-9. 
225. Hannenhalli S, Kaestner KH. The evolution of Fox genes and their role in development and 
disease. Nat Rev Genet. 2009;10(4):233-40. 
226. Robinson JLL, Holmes KA, Carroll JS. FOXA1 mutations in hormone-dependent cancers. 
Front Oncol. 2013;3:20. 
227. Robinson JLL, Macarthur S, Ross-Innes CS, Tilley WD, Neal DE, Mills IG, et al. Androgen 
receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO J. 
2011;30(15):3019-27. 
228. Hurtado A, Holmes KA, Ross-Innes CS, Schmidt D, Carroll JS. FOXA1 is a key determinant of 
estrogen receptor function and endocrine response. Nat Genet. 2011;43(1):27-33. 
References 
 86 
229. Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, et al. FOXA1 expression in 
breast cancer--correlation with luminal subtype A and survival. Clin Cancer Res. 2007;13(15 Pt 1):4415-
21. 
230. Hisamatsu Y, Tokunaga E, Yamashita N, Akiyoshi S, Okada S, Nakashima Y, et al. Impact of 
FOXA1 expression on the prognosis of patients with hormone receptor-positive breast cancer. Ann 
Surg Oncol. 2012;19(4):1145-52. 
231. Jain RK, Mehta RJ, Nakshatri H, Idrees MT, Badve SS. High-level expression of forkhead-box 
protein A1 in metastatic prostate cancer. Histopathology. 2011;58(5):766-72. 
232. Gerhardt J, Montani M, Wild P, Beer M, Huber F, Hermanns T, et al. FOXA1 promotes tumor 
progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer. 
Am J Pathol. 2012;180(2):848-61. 
233. Sahu B, Laakso M, Ovaska K, Mirtti T, Lundin J, Rannikko A, et al. Dual role of FoxA1 in 
androgen receptor binding to chromatin, androgen signalling and prostate cancer. EMBO J. 
2011;30(19):3962-76. 
234. Wang D, Garcia-Bassets I, Benner C, Li W, Su X, Zhou Y, et al. Reprogramming transcription 
by distinct classes of enhancers functionally defined by eRNA. Nature. 2011;474(7351):390-4. 
235. Robinson JLL, Hickey TE, Warren AY, Vowler SL, Carroll T, Lamb AD, et al. Elevated levels of 
FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPC-like phenotype. Oncogene. 
2014;33(50):5666-74. 
236. Zhang C, Wang L, Wu D, Chen H, Chen Z, Thomas-Ahner JM, et al. Definition of a FoxA1 
Cistrome that is crucial for G1 to S-phase cell-cycle transit in castration-resistant prostate cancer. Cancer 
Res. 2011;71(21):6738-48. 
237. Dong X-Y, Chen C, Sun X, Guo P, Vessella RL, Wang R-X, et al. FOXO1A is a candidate for the 
13q14 tumor suppressor gene inhibiting androgen receptor signaling in prostate cancer. Cancer Res. 
2006;66(14):6998-7006. 
238. Mediwala SN, Sun H, Szafran AT, Hartig SM, Sonpavde G, Hayes TG, et al. The activity of the 
androgen receptor variant AR-V7 is regulated by FOXO1 in a PTEN-PI3K-AKT-dependent way. Prostate. 
2013;73(3):267-77. 
239. Liu P, Li S, Gan L, Kao TP, Huang H. A transcription-independent function of FOXO1 in 
inhibition of androgen-independent activation of the androgen receptor in prostate cancer cells. 
Cancer Res. 2008;68(24):10290-9. 
240. Ma Q, Fu W, Li P, Nicosia SV, Jenster G, Zhang X, et al. FoxO1 mediates PTEN suppression of 
androgen receptor N- and C-terminal interactions and coactivator recruitment. Mol Endocrinol. 
2009;23(2):213-25. 
241. Gan L, Chen S, Wang Y, Watahiki A, Bohrer L, Sun Z, et al. Inhibition of the androgen 
receptor as a novel mechanism of taxol chemotherapy in prostate cancer. Cancer Res. 
2009;69(21):8386-94. 
242. Wang L, Liu R, Li W, Chen C, Katoh H, Chen G-Y, et al. Somatic single hits inactivate the X-
linked tumor suppressor FOXP3 in the prostate. Cancer Cell. 2009;16(4):336-46. 
243. Schneider A, Brand T, Zweigerdt R, Arnold H. Targeted disruption of the Nkx3.1 gene in 
mice results in morphogenetic defects of minor salivary glands: parallels to glandular duct 
morphogenesis in prostate. Mech Dev. 2000;95(1-2):163-74. 
244. Tanaka M, Komuro I, Inagaki H, Jenkins NA, Copeland NG, Izumo S. Nkx3.1, a murine 
homolog of Ddrosophila bagpipe, regulates epithelial ductal branching and proliferation of the 
prostate and palatine glands. Dev Dyn. 2000;219(2):248-60. 
245. Tribioli C, Lufkin T. The murine Bapx1 homeobox gene plays a critical role in embryonic 
development of the axial skeleton and spleen. Development. 1999;126(24):5699-711. 
246. Bhatia-Gaur R, Donjacour AA, Sciavolino PJ, Kim M, Desai N, Young P, et al. Roles for Nkx3.1 
in prostate development and cancer. Genes Dev. 1999;13(8):966-77. 
247. Bieberich CJ, Fujita K, He WW, Jay G. Prostate-specific and androgen-dependent expression 
of a novel homeobox gene. J Biol Chem. 1996;271(50):31779-82. 
248. Emmert-Buck MR, Vocke CD, Pozzatti RO, Duray PH, Jennings SB, Florence CD, et al. Allelic 
loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. Cancer Res. 
1995;55(14):2959-62. 
249. Vocke CD, Pozzatti RO, Bostwick DG, Florence CD, Jennings SB, Strup SE, et al. Analysis of 99 
microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21. 
Cancer Res. 1996;56(10):2411-6. 
250. He WW, Sciavolino PJ, Wing J, Augustus M, Hudson P, Meissner PS, et al. A novel human 
prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently 
deleted in prostate cancer. Genomics. 1997;43(1):69-77. 
251. Irer B, Toylu A, Aslan G, Celebi I, Yorukoglu K, Atabey N. Increased expression of NKX3.1 in 
benign prostatic hyperplasia. Urology. 2009;73(5):1140-4. 
References 
 
 
87 
252. Abdulkadir SA, Magee JA, Peters TJ, Kaleem Z, Naughton CK, Humphrey PA, et al. 
Conditional loss of Nkx3.1 in adult mice induces prostatic intraepithelial neoplasia. Mol Cell Biol. 
2002;22(5):1495-503. 
253. Kim MJ, Bhatia-Gaur R, Banach-Petrosky WA, Desai N, Wang Y, Hayward SW, et al. Nkx3.1 
mutant mice recapitulate early stages of prostate carcinogenesis. Cancer Res. 2002;62(11):2999-3004. 
254. Markowski MC, Bowen C, Gelmann EP. Inflammatory cytokines induce phosphorylation and 
ubiquitination of prostate suppressor protein NKX3.1. Cancer Res. 2008;68(17):6896-901. 
255. Ouyang X, DeWeese TL, Nelson WG, Abate-Shen C. Loss-of-function of Nkx3.1 promotes 
increased oxidative damage in prostate carcinogenesis. Cancer Res. 2005;65(15):6773-9. 
256. Abate-Shen C, Shen MM, Gelmann E. Integrating differentiation and cancer: the Nkx3.1 
homeobox gene in prostate organogenesis and carcinogenesis. Differentiation. 2008;76(6):717-27. 
257. Kim MJ, Cardiff RD, Desai N, Banach-Petrosky WA, Parsons R, Shen MM, et al. Cooperativity 
of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci U S 
A. 2002;99(5):2884-9. 
258. Lei Q, Jiao J, Xin L, Chang C-J, Wang S, Gao J, et al. NKX3.1 stabilizes p53, inhibits AKT 
activation, and blocks prostate cancer initiation caused by PTEN loss. Cancer Cell. 2006;9(5):367-78. 
259. Anderson PD, McKissic SA, Logan M, Roh M, Franco OE, Wang J, et al. Nkx3.1 and Myc 
crossregulate shared target genes in mouse and human prostate tumorigenesis. J Clin Invest. 
2012;122(5):1907-19. 
260. Iwata T, Schultz D, Hicks J, Hubbard GK, Mutton LN, Lotan TL, et al. MYC overexpression 
induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells. PLoS 
One. 2010;5(2):e9427. 
261. Jung C, Kim R-S, Zhang H-J, Lee S-J, Jeng M-H. HOXB13 induces growth suppression of 
prostate cancer cells as a repressor of hormone-activated androgen receptor signaling. Cancer Res. 
2004;64(24):9185-92. 
262. Kim Y-R, Kim I-J, Kang TW, Choi C, Kim KK, Kim MS, et al. HOXB13 downregulates 
intracellular zinc and increases NF-κB signaling to promote prostate cancer metastasis. Oncogene. 
2014;33(37):4558-67. 
263. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging 
mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol. 2010;11(5):329-41. 
264. Martini M, De Santis MC, Braccini L, Gulluni F, Hirsch E. PI3K/AKT signaling pathway and 
cancer: an updated review. Ann Med. 2014;46(6):372-83. 
265. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid 
second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 1998;273(22):13375-8. 
266. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative protein tyrosine 
phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275(5308):1943-
7. 
267. Yoshimoto M, Cunha IW, Coudry RA, Fonseca FP, Torres CH, Soares FA, et al. FISH analysis of 
107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J 
Cancer. 2007;97(5):678-85. 
268. Mulholland DJ, Tran LM, Li Y, Cai H, Morim A, Wang S, et al. Cell autonomous role of PTEN in 
regulating castration-resistant prostate cancer growth. Cancer Cell. 2011;19(6):792-804. 
269. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, et al. 
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate 
cancer. Cancer Cell. 2011;19(5):575-86. 
270. Wang Y, Romigh T, He X, Tan M-H, Orloff MS, Silverman RH, et al. Differential regulation of 
PTEN expression by androgen receptor in prostate and breast cancers. Oncogene. 2011;30(42):4327-38. 
271. Hayward WS, Neel BG, Astrin SM. Activation of a cellular onc gene by promoter insertion in 
ALV-induced lymphoid leukosis. Nature. 1981;290(5806):475-80. 
272. Cory S, Gerondakis S, Adams JM. Interchromosomal recombination of the cellular 
oncogene c-myc with the immunoglobulin heavy chain locus in murine plasmacytomas is a reciprocal 
exchange. EMBO J. 1983;2(5):697-703. 
273. Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM. Human c-myc onc 
gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl 
Acad Sci U S A. 1982;79(24):7824-7. 
274. Taub R, Kirsch I, Morton C, Lenoir G, Swan D, Tronick S, et al. Translocation of the c-myc 
gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine 
plasmacytoma cells. Proc Natl Acad Sci U S A. 1982;79(24):7837-41. 
275. Li Z, Van Calcar S, Qu C, Cavenee WK, Zhang MQ, Ren B. A global transcriptional regulatory 
role for c-Myc in Burkitt's lymphoma cells. Proc Natl Acad Sci U S A. 2003;100(14):8164-9. 
276. Liu Y-C, Li F, Handler J, Huang CRL, Xiang Y, Neretti N, et al. Global regulation of nucleotide 
biosynthetic genes by c-Myc. PLoS One. 2008;3(7):e2722. 
References 
 88 
277. Zeller KI, Zhao X, Lee CWH, Chiu KP, Yao F, Yustein JT, et al. Global mapping of c-Myc 
binding sites and target gene networks in human B cells. Proc Natl Acad Sci U S A. 2006;103(47):17834-
9. 
278. Alitalo K, Schwab M, Lin CC, Varmus HE, Bishop JM. Homogeneously staining chromosomal 
regions contain amplified copies of an abundantly expressed cellular oncogene (c-myc) in malignant 
neuroendocrine cells from a human colon carcinoma. Proc Natl Acad Sci U S A. 1983;80(6):1707-11. 
279. Riou G, Barrois M, Lê MG, George M, Le Doussal V, Haie C. C-myc proto-oncogene 
expression and prognosis in early carcinoma of the uterine cervix. Lancet. 1987;1(8536):761-3. 
280. Yokota J, Wada M, Yoshida T, Noguchi M, Terasaki T, Shimosato Y, et al. Heterogeneity of 
lung cancer cells with respect to the amplification and rearrangement of myc family oncogenes. 
Oncogene. 1988;2(6):607-11. 
281. Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, Sander C. Emerging landscape of 
oncogenic signatures across human cancers. Nat Genet. 2013;45(10):1127-33. 
282. Consortium EP. The ENCODE (ENCyclopedia Of DNA Elements) Project. Science. 
2004;306(5696):636-40. 
283. Wilson A, Murphy MJ, Oskarsson T, Kaloulis K, Bettess MD, Oser GM, et al. c-Myc controls 
the balance between hematopoietic stem cell self-renewal and differentiation. Genes Dev. 
2004;18(22):2747-63. 
284. Lister R, Pelizzola M, Dowen RH, Hawkins RD, Hon G, Tonti-Filippini J, et al. Human DNA 
methylomes at base resolution show widespread epigenomic differences. Nature. 2009;462(7271):315-
22. 
285. Chen X, Xu H, Yuan P, Fang F, Huss M, Vega VB, et al. Integration of external signaling 
pathways with the core transcriptional network in embryonic stem cells. Cell. 2008;133(6):1106-17. 
286. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and 
adult fibroblast cultures by defined factors. Cell. 2006;126(4):663-76. 
287. Amati B, Brooks MW, Levy N, Littlewood TD, Evan GI, Land H. Oncogenic activity of the c-
Myc protein requires dimerization with Max. Cell. 1993;72(2):233-45. 
288. Prendergast GC, Ziff EB. Methylation-sensitive sequence-specific DNA binding by the c-Myc 
basic region. Science. 1991;251(4990):186-9. 
289. Ayer DE, Eisenman RN. A switch from Myc:Max to Mad:Max heterocomplexes accompanies 
monocyte/macrophage differentiation. Genes Dev. 1993;7(11):2110-9. 
290. Hurlin PJ, Quéva C, Eisenman RN. Mnt, a novel Max-interacting protein is coexpressed with 
Myc in proliferating cells and mediates repression at Myc binding sites. Genes Dev. 1997;11(1):44-58. 
291. Ayer DE, Kretzner L, Eisenman RN. Mad: a heterodimeric partner for Max that antagonizes 
Myc transcriptional activity. Cell. 1993;72(2):211-22. 
292. Nie Z, Hu G, Wei G, Cui K, Yamane A, Resch W, et al. c-Myc is a universal amplifier of 
expressed genes in lymphocytes and embryonic stem cells. Cell. 2012;151(1):68-79. 
293. Lin CY, Lovén J, Rahl PB, Paranal RM, Burge CB, Bradner JE, et al. Transcriptional 
amplification in tumor cells with elevated c-Myc. Cell. 2012;151(1):56-67. 
294. Xiao Q, Claassen G, Shi J, Adachi S, Sedivy J, Hann SR. Transactivation-defective c-MycS 
retains the ability to regulate proliferation and apoptosis. Genes Dev. 1998;12(24):3803-8. 
295. Staller P, Peukert K, Kiermaier A, Seoane J, Lukas J, Karsunky H, et al. Repression of 
p15INK4b expression by Myc through association with Miz-1. Nat Cell Biol. 2001;3(4):392-9. 
296. van Riggelen J, Müller J, Otto T, Beuger V, Yetil A, Choi PS, et al. The interaction between 
Myc and Miz1 is required to antagonize TGFbeta-dependent autocrine signaling during lymphoma 
formation and maintenance. Genes Dev. 2010;24(12):1281-94. 
297. Walz S, Lorenzin F, Morton J, Wiese KE, von Eyss B, Herold S, et al. Activation and repression 
by oncogenic MYC shape tumour-specific gene expression profiles. Nature. 2014;511(7510):483-7. 
298. McMahon SB, Van Buskirk HA, Dugan KA, Copeland TD, Cole MD. The novel ATM-related 
protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins. Cell. 1998;94(3):363-74. 
299. Park J, Kunjibettu S, McMahon SB, Cole MD. The ATM-related domain of TRRAP is required 
for histone acetyltransferase recruitment and Myc-dependent oncogenesis. Genes Dev. 
2001;15(13):1619-24. 
300. Frank SR, Schroeder M, Fernandez P, Taubert S, Amati B. Binding of c-Myc to chromatin 
mediates mitogen-induced acetylation of histone H4 and gene activation. Genes Dev. 
2001;15(16):2069-82. 
301. Frank SR, Parisi T, Taubert S, Fernandez P, Fuchs M, Chan H-M, et al. MYC recruits the TIP60 
histone acetyltransferase complex to chromatin. EMBO Rep. 2003;4(6):575-80. 
302. Kusch T, Florens L, Macdonald WH, Swanson SK, Glaser RL, Yates JR, et al. Acetylation by 
Tip60 is required for selective histone variant exchange at DNA lesions. Science. 2004;306(5704):2084-7. 
303. Vervoorts J, Lüscher-Firzlaff JM, Rottmann S, Lilischkis R, Walsemann G, Dohmann K, et al. 
Stimulation of c-MYC transcriptional activity and acetylation by recruitment of the cofactor CBP. EMBO 
Rep. 2003;4(5):484-90. 
References 
 
 
89 
304. Fuchs M, Gerber J, Drapkin R, Sif S, Ikura T, Ogryzko V, et al. The p400 complex is an 
essential E1A transformation target. Cell. 2001;106(3):297-307. 
305. Jónsson ZO, Jha S, Wohlschlegel JA, Dutta A. Rvb1p/Rvb2p recruit Arp5p and assemble a 
functional Ino80 chromatin remodeling complex. Mol Cell. 2004;16(3):465-77. 
306. Wood MA, McMahon SB, Cole MD. An ATPase/helicase complex is an essential cofactor for 
oncogenic transformation by c-Myc. Mol Cell. 2000;5(2):321-30. 
307. Kanazawa S, Soucek L, Evan G, Okamoto T, Peterlin BM. c-Myc recruits P-TEFb for 
transcription, cellular proliferation and apoptosis. Oncogene. 2003;22(36):5707-11. 
308. Eberhardy SR, Farnham PJ. Myc recruits P-TEFb to mediate the final step in the 
transcriptional activation of the cad promoter. J Biol Chem. 2002;277(42):40156-62. 
309. Brenner C, Deplus R, Didelot C, Loriot A, Viré E, De Smet C, et al. Myc represses transcription 
through recruitment of DNA methyltransferase corepressor. EMBO J. 2005;24(2):336-46. 
310. Eberhardy SR, Farnham PJ. c-Myc mediates activation of the cad promoter via a post-RNA 
polymerase II recruitment mechanism. J Biol Chem. 2001;276(51):48562-71. 
311. Barsyte-Lovejoy D, Mao DYL, Penn LZ. c-Myc represses the proximal promoters of 
GADD45a and GADD153 by a post-RNA polymerase II recruitment mechanism. Oncogene. 
2004;23(19):3481-6. 
312. Adhikary S, Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat 
Rev Mol Cell Biol. 2005;6(8):635-45. 
313. Rahl PB, Lin CY, Seila AC, Flynn RA, McCuine S, Burge CB, et al. c-Myc regulates 
transcriptional pause release. Cell. 2010;141(3):432-45. 
314. Ji H, Wu G, Zhan X, Nolan A, Koh C, De Marzo A, et al. Cell-type independent MYC target 
genes reveal a primordial signature involved in biomass accumulation. PLoS One. 2011;6(10):e26057. 
315. van Riggelen J, Yetil A, Felsher DW. MYC as a regulator of ribosome biogenesis and protein 
synthesis. Nat Rev Cancer. 2010;10(4):301-9. 
316. Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang X-Y, Pfeiffer HK, et al. Myc regulates a 
transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. 
Proc Natl Acad Sci U S A. 2008;105(48):18782-7. 
317. Grandori C, Gomez-Roman N, Felton-Edkins ZA, Ngouenet C, Galloway DA, Eisenman RN, et 
al. c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA 
polymerase I. Nat Cell Biol. 2005;7(3):311-8. 
318. Jansen-Dürr P, Meichle A, Steiner P, Pagano M, Finke K, Botz J, et al. Differential modulation 
of cyclin gene expression by MYC. Proc Natl Acad Sci U S A. 1993;90(8):3685-9. 
319. Liu W, Le A, Hancock C, Lane AN, Dang CV, Fan TW-M, et al. Reprogramming of proline and 
glutamine metabolism contributes to the proliferative and metabolic responses regulated by 
oncogenic transcription factor c-MYC. Proc Natl Acad Sci U S A. 2012;109(23):8983-8. 
320. Koh CM, Gurel B, Sutcliffe S, Aryee MJ, Schultz D, Iwata T, et al. Alterations in nucleolar 
structure and gene expression programs in prostatic neoplasia are driven by the MYC oncogene. Am J 
Pathol. 2011;178(4):1824-34. 
321. Priolo C, Pyne S, Rose J, Regan ER, Zadra G, Photopoulos C, et al. AKT1 and MYC induce 
distinctive metabolic fingerprints in human prostate cancer. Cancer Res. 2014;74(24):7198-204. 
322. Van Den Berg C, Guan XY, Von Hoff D, Jenkins R, Griffin C, Kallioniemi O, et al. DNA 
sequence amplification in human prostate cancer identified by chromosome microdissection: potential 
prognostic implications. Clin Cancer Res. 1995;1(1):11-8. 
323. van Dekken H, Alers JC, Damen IAAJ, Vissers KJ, Krijtenburg P-J, Hoedemaeker RF, et al. 
Genetic evaluation of localized prostate cancer in a cohort of forty patients: gain of distal 8q 
discriminates between progressors and nonprogressors. Lab Invest. 2003;83(6):789-96. 
324. Hawksworth D, Ravindranath L, Chen Y, Furusato B, Sesterhenn IA, McLeod DG, et al. 
Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence. Prostate 
Cancer Prostatic Dis. 2010;13(4):311-5. 
325. Sotelo J, Esposito D, Duhagon MA, Banfield K, Mehalko J, Liao H, et al. Long-range 
enhancers on 8q24 regulate c-Myc. Proc Natl Acad Sci U S A. 2010;107(7):3001-5. 
326. Bodescot M, Brison O. Characterization of new human c-myc mRNA species produced by 
alternative splicing. Gene. 1996;174(1):115-20. 
327. Arsura M, Deshpande A, Hann SR, Sonenshein GE. Variant Max protein, derived by 
alternative splicing, associates with c-Myc in vivo and inhibits transactivation. Mol Cell Biol. 
1995;15(12):6702-9. 
328. Cobbold LC, Wilson LA, Sawicka K, King HA, Kondrashov AV, Spriggs KA, et al. Upregulated 
c-myc expression in multiple myeloma by internal ribosome entry results from increased interactions 
with and expression of PTB-1 and YB-1. Oncogene. 2010;29(19):2884-91. 
329. Jo OD, Martin J, Bernath A, Masri J, Lichtenstein A, Gera J. Heterogeneous nuclear 
ribonucleoprotein A1 regulates cyclin D1 and c-myc internal ribosome entry site function through Akt 
signaling. J Biol Chem. 2008;283(34):23274-87. 
References 
 90 
330. Noguchi K, Kitanaka C, Yamana H, Kokubu A, Mochizuki T, Kuchino Y. Regulation of c-Myc 
through phosphorylation at Ser-62 and Ser-71 by c-Jun N-terminal kinase. J Biol Chem. 
1999;274(46):32580-7. 
331. Wang X, Cunningham M, Zhang X, Tokarz S, Laraway B, Troxell M, et al. Phosphorylation 
regulates c-Myc's oncogenic activity in the mammary gland. Cancer Res. 2011;71(3):925-36. 
332. Kim JY, Valencia T, Abu-Baker S, Linares J, Lee SJ, Yajima T, et al. c-Myc phosphorylation by 
PKCζ represses prostate tumorigenesis. Proc Natl Acad Sci U S A. 2013;110(16):6418-23. 
333. Itkonen HM, Minner S, Guldvik IJ, Sandmann MJ, Tsourlakis MC, Berge V, et al. O-GlcNAc 
transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer 
cells. Cancer Res. 2013;73(16):5277-87. 
334. Gil J, Kerai P, Lleonart M, Bernard D, Cigudosa JC, Peters G, et al. Immortalization of primary 
human prostate epithelial cells by c-Myc. Cancer Res. 2005;65(6):2179-85. 
335. Wang J, Kobayashi T, Floc'h N, Kinkade CW, Aytes A, Dankort D, et al. B-Raf activation 
cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer. Cancer Res. 
2012;72(18):4765-76. 
336. Kokontis J, Takakura K, Hay N, Liao S. Increased androgen receptor activity and altered c-
myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res. 
1994;54(6):1566-73. 
337. Ni M, Chen Y, Fei T, Li D, Lim E, Liu XS, et al. Amplitude modulation of androgen signaling 
by c-MYC. Genes Dev. 2013;27(7):734-48. 
338. Koh CM, Bieberich CJ, Dang CV, Nelson WG, Yegnasubramanian S, De Marzo AM. MYC and 
Prostate Cancer. Genes Cancer. 2010;1(6):617-28. 
339. Zhao Z, Tavoosidana G, Sjölinder M, Göndör A, Mariano P, Wang S, et al. Circular 
chromosome conformation capture (4C) uncovers extensive networks of epigenetically regulated intra- 
and interchromosomal interactions. Nat Genet. 2006;38(11):1341-7. 
340. Dostie J, Dekker J. Mapping networks of physical interactions between genomic elements 
using 5C technology. Nat Protoc. 2007;2(4):988-1002. 
341. Dekker J, Rippe K, Dekker M, Kleckner N. Capturing chromosome conformation. Science. 
2002;295(5558):1306-11. 
342. Karthaus WR, Iaquinta PJ, Drost J, Gracanin A, van Boxtel R, Wongvipat J, et al. Identification 
of multipotent luminal progenitor cells in human prostate organoid cultures. Cell. 2014;159(1):163-75. 
343. Gao D, Vela I, Sboner A, Iaquinta PJ, Karthaus WR, Gopalan A, et al. Organoid cultures 
derived from patients with advanced prostate cancer. Cell. 2014;159(1):176-87. 
344. Horoszewicz JS, Leong SS, Chu TM, Wajsman ZL, Friedman M, Papsidero L, et al. The LNCaP 
cell line--a new model for studies on human prostatic carcinoma. Prog Clin Biol Res. 1980;37:115-32. 
345. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, et al. LNCaP model of 
human prostatic carcinoma. Cancer Res. 1983;43(4):1809-18. 
346. Korenchuk S, Lehr JE, MClean L, Lee YG, Whitney S, Vessella R, et al. VCaP, a cell-based 
model system of human prostate cancer. In Vivo. 2001;15(2):163-8. 
347. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic 
interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391(6669):806-11. 
348. Hamilton AJ, Baulcombe DC. A species of small antisense RNA in posttranscriptional gene 
silencing in plants. Science. 1999;286(5441):950-2. 
349. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-
nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411(6836):494-8. 
350. Burger K, Gullerova M. Swiss army knives: non-canonical functions of nuclear Drosha and 
Dicer. Nat Rev Mol Cell Biol. 2015. 
351. Dysvik B, Jonassen I. J-Express: exploring gene expression data using Java. Bioinformatics. 
2001;17(4):369-70. 
352. de Hoon MJL, Imoto S, Nolan J, Miyano S. Open source clustering software. Bioinformatics. 
2004;20(9):1453-4. 
353. Carmona-Saez P, Chagoyen M, Tirado F, Carazo JM, Pascual-Montano A. GENECODIS: a 
web-based tool for finding significant concurrent annotations in gene lists. Genome Biol. 2007;8(1):R3. 
354. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene 
lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44-57. 
355. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set 
enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. 
Proc Natl Acad Sci U S A. 2005;102(43):15545-50. 
356. Solomon MJ, Larsen PL, Varshavsky A. Mapping protein-DNA interactions in vivo with 
formaldehyde: evidence that histone H4 is retained on a highly transcribed gene. Cell. 1988;53(6):937-
47. 
357. Schmidt D, Wilson MD, Spyrou C, Brown GD, Hadfield J, Odom DT. ChIP-seq: using high-
throughput sequencing to discover protein-DNA interactions. Methods. 2009;48(3):240-8. 
References 
 
 
91 
358. Blankenberg D, Von Kuster G, Coraor N, Ananda G, Lazarus R, Mangan M, et al. Galaxy: a 
web-based genome analysis tool for experimentalists. Curr Protoc Mol Biol. 2010;Chapter 19:Unit 
19.0.1-21. 
359. Liu T, Ortiz JA, Taing L, Meyer CA, Lee B, Zhang Y, et al. Cistrome: an integrative platform for 
transcriptional regulation studies. Genome Biol. 2011;12(8):R83. 
360. Nair NU, Sahu AD, Bucher P, Moret BME. ChIPnorm: a statistical method for normalizing and 
identifying differential regions in histone modification ChIP-seq libraries. PLoS One. 2012;7(8):e39573. 
361. Liang K, Keleş S. Normalization of ChIP-seq data with control. BMC Bioinformatics. 
2012;13:199. 
362. Orlando DA, Chen MW, Brown VE, Solanki S, Choi YJ, Olson ER, et al. Quantitative ChIP-Seq 
normalization reveals global modulation of the epigenome. Cell Rep. 2014;9(3):1163-70. 
363. Landt SG, Marinov GK, Kundaje A, Kheradpour P, Pauli F, Batzoglou S, et al. ChIP-seq 
guidelines and practices of the ENCODE and modENCODE consortia. Genome Res. 2012;22(9):1813-31. 
364. Serandour AA, Brown GD, Cohen JD, Carroll JS. Development of an Illumina-based ChIP-
exonuclease method provides insight into FoxA1-DNA binding properties. Genome Biol. 
2013;14(12):R147. 
365. Tavassoli P, Wafa LA, Cheng H, Zoubeidi A, Fazli L, Gleave M, et al. TAF1 differentially 
enhances androgen receptor transcriptional activity via its N-terminal kinase and ubiquitin-activating 
and -conjugating domains. Mol Endocrinol. 2010;24(4):696-708. 
366. Annala M, Kivinummi K, Tuominen J, Karakurt S, Granberg K, Latonen L, et al. Recurrent 
SKIL-activating rearrangements in ETS-negative prostate cancer. Oncotarget. 2015. 
367. Bruchmann A, Roller C, Walther TV, Schäfer G, Lehmusvaara S, Visakorpi T, et al. Bcl-2 
associated athanogene 5 (Bag5) is overexpressed in prostate cancer and inhibits ER-stress induced 
apoptosis. BMC Cancer. 2013;13:96. 
368. Urbanucci A, Sahu B, Seppälä J, Larjo A, Latonen LM, Waltering KK, et al. Overexpression of 
androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer. 
Oncogene. 2012;31(17):2153-63. 
369. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in 
primary solid tumors. Nat Genet. 2003;33(1):49-54. 
370. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, et al. Integrative 
molecular concept modeling of prostate cancer progression. Nat Genet. 2007;39(1):41-51. 
371. Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, et al. Integrative genomic 
and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell. 
2005;8(5):393-406. 
372. Atlas TCG. TCGA Data Portal 2014 [cited 2015 15 June 2015]. Available from: https://tcga-
data.nci.nih.gov/tcga/. 
373. Richardson AM, Woodson K, Wang Y, Rodriguez-Canales J, Erickson HS, Tangrea MA, et al. 
Global expression analysis of prostate cancer-associated stroma and epithelia. Diagn Mol Pathol. 
2007;16(4):189-97. 
374. Di Vizio D, Morello M, Sotgia F, Pestell RG, Freeman MR, Lisanti MP. An absence of stromal 
caveolin-1 is associated with advanced prostate cancer, metastatic disease and epithelial Akt activation. 
Cell Cycle. 2009;8(15):2420-4. 
375. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, et al. ONCOMINE: a 
cancer microarray database and integrated data-mining platform. Neoplasia. 2004;6(1):1-6. 
376. Ohtsubo K, Marth JD. Glycosylation in cellular mechanisms of health and disease. Cell. 
2006;126(5):855-67. 
377. Van den Steen P, Rudd PM, Dwek RA, Opdenakker G. Concepts and principles of O-linked 
glycosylation. Crit Rev Biochem Mol Biol. 1998;33(3):151-208. 
378. Schwarz F, Aebi M. Mechanisms and principles of N-linked protein glycosylation. Curr Opin 
Struct Biol. 2011;21(5):576-82. 
379. Wellen KE, Lu C, Mancuso A, Lemons JMS, Ryczko M, Dennis JW, et al. The hexosamine 
biosynthetic pathway couples growth factor-induced glutamine uptake to glucose metabolism. Genes 
Dev. 2010;24(24):2784-99. 
380. Itkonen HM, Engedal N, Babaie E, Luhr M, Guldvik IJ, Minner S, et al. UAP1 is overexpressed 
in prostate cancer and is protective against inhibitors of N-linked glycosylation. Oncogene. 2014. 
381. Cooperberg MR, Davicioni E, Crisan A, Jenkins RB, Ghadessi M, Karnes RJ. Combined value 
of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a 
high-risk prostatectomy cohort. Eur Urol. 2015;67(2):326-33. 
382. Klein EA, Yousefi K, Haddad Z, Choeurng V, Buerki C, Stephenson AJ, et al. A genomic 
classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-
risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy. Eur Urol. 
2015;67(4):778-86. 
References 
 92 
383. Den RB, Yousefi K, Trabulsi EJ, Abdollah F, Choeurng V, Feng FY, et al. Genomic classifier 
identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation 
therapy. J Clin Oncol. 2015;33(8):944-51. 
384. Stephan C, Rittenhouse H, Cammann H, Lein M, Schrader M, Deger S, et al. New markers 
and multivariate models for prostate cancer detection. Anticancer Res. 2009;29(7):2589-600. 
385. Dijkstra S, Mulders PFA, Schalken JA. Clinical use of novel urine and blood based prostate 
cancer biomarkers: a review. Clin Biochem. 2014;47(10-11):889-96. 
386. Hessels D, Klein Gunnewiek JMT, van Oort I, Karthaus HFM, van Leenders GJL, van Balken B, 
et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol. 
2003;44(1):8-15; discussion -6. 
387. Halvorsen OJ, Rostad K, Øyan AM, Puntervoll H, Bø TH, Stordrange L, et al. Increased 
expression of SIM2-s protein is a novel marker of aggressive prostate cancer. Clin Cancer Res. 
2007;13(3):892-7. 
388. Leyten GHJM, Hessels D, Smit FP, Jannink SA, de Jong H, Melchers WJG, et al. Identification 
of a Candidate Gene Panel for the Early Diagnosis of Prostate Cancer. Clin Cancer Res. 2015. 
389. Ramos-Montoya A, Lamb AD, Russell R, Carroll T, Jurmeister S, Galeano-Dalmau N, et al. 
HES6 drives a critical AR transcriptional programme to induce castration-resistant prostate cancer 
through activation of an E2F1-mediated cell cycle network. EMBO Mol Med. 2014;6(5):651-61. 
390. Kim J, Chu J, Shen X, Wang J, Orkin SH. An extended transcriptional network for 
pluripotency of embryonic stem cells. Cell. 2008;132(6):1049-61. 
391. Kidder BL, Yang J, Palmer S. Stat3 and c-Myc genome-wide promoter occupancy in 
embryonic stem cells. PLoS One. 2008;3(12):e3932. 
392. Nyhan WL. Nucleotide Synthesis via Salvage Pathway.  eLS John Wiley & Sons, Ltd: 
Chichester2014. 
393. Keller KE, Tan IS, Lee Y-S. SAICAR stimulates pyruvate kinase isoform M2 and promotes 
cancer cell survival in glucose-limited conditions. Science. 2012;338(6110):1069-72. 
394. He Y, Mou Z, Li W, Liu B, Fu T, Zhao S, et al. Identification of IMPDH2 as a tumor-associated 
antigen in colorectal cancer using immunoproteomics analysis. Int J Colorectal Dis. 2009;24(11):1271-9. 
395. Sweeney MJ, Gerzon K, Harris PN, Holmes RE, Poore GA, Williams RH. Experimental 
antitumor activity and preclinical toxicology of mycophenolic acid. Cancer Res. 1972;32(9):1795-802. 
396. Strittmatter SM. Overcoming Drug Development Bottlenecks With Repurposing: Old drugs 
learn new tricks. Nat Med. 2014;20(6):590-1. 
397. Shim JS, Liu JO. Recent advances in drug repositioning for the discovery of new anticancer 
drugs. Int J Biol Sci. 2014;10(7):654-63. 
398. Tsai RYL, McKay RDG. A nucleolar mechanism controlling cell proliferation in stem cells and 
cancer cells. Genes Dev. 2002;16(23):2991-3003. 
399. Huang M, Itahana K, Zhang Y, Mitchell BS. Depletion of guanine nucleotides leads to the 
Mdm2-dependent proteasomal degradation of nucleostemin. Cancer Res. 2009;69(7):3004-12. 
400. Ma H, Pederson T. Depletion of the nucleolar protein nucleostemin causes G1 cell cycle 
arrest via the p53 pathway. Mol Biol Cell. 2007;18(7):2630-5. 
401. Sun X-X, Dai M-S, Lu H. Mycophenolic acid activation of p53 requires ribosomal proteins L5 
and L11. J Biol Chem. 2008;283(18):12387-92. 
402. Ren D, Wang M, Guo W, Zhao X, Tu Xa, Huang S, et al. Wild-type p53 suppresses the 
epithelial-mesenchymal transition and stemness in PC-3 prostate cancer cells by modulating miR̻145. 
Int J Oncol. 2013;42(4):1473-81. 
403. Benassi B, Flavin R, Marchionni L, Zanata S, Pan Y, Chowdhury D, et al. MYC is activated by 
USP2a-mediated modulation of microRNAs in prostate cancer. Cancer Discov. 2012;2(3):236-47. 
404. Sahu B, Laakso M, Pihlajamaa P, Ovaska K, Sinielnikov I, Hautaniemi S, et al. FoxA1 specifies 
unique androgen and glucocorticoid receptor binding events in prostate cancer cells. Cancer Res. 
2013;73(5):1570-80. 
405. Pellakuru LG, Iwata T, Gurel B, Schultz D, Hicks J, Bethel C, et al. Global levels of H3K27me3 
track with differentiation in vivo and are deregulated by MYC in prostate cancer. Am J Pathol. 
2012;181(2):560-9. 
406. Ernst J, Kheradpour P, Mikkelsen TS, Shoresh N, Ward LD, Epstein CB, et al. Mapping and 
analysis of chromatin state dynamics in nine human cell types. Nature. 2011;473(7345):43-9. 
407. Nelson PS, Clegg N, Arnold H, Ferguson C, Bonham M, White J, et al. The program of 
androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci U S A. 
2002;99(18):11890-5. 
408. Schuhmacher M, Kohlhuber F, Hölzel M, Kaiser C, Burtscher H, Jarsch M, et al. The 
transcriptional program of a human B cell line in response to Myc. Nucleic Acids Res. 2001;29(2):397-
406. 
References 
 
 
93 
409. Hoefer J, Kern J, Ofer P, Eder IE, Schäfer G, Dietrich D, et al. SOCS2 correlates with 
malignancy and exerts growth-promoting effects in prostate cancer. Endocr Relat Cancer. 
2014;21(2):175-87. 
410. Zhu J-g, Dai Q-s, Han Z-d, He H-c, Mo R-j, Chen G, et al. Expression of SOCSs in human 
prostate cancer and their association in prognosis. Mol Cell Biochem. 2013;381(1-2):51-9. 
411. Khan AP, Rajendiran TM, Ateeq B, Asangani IA, Athanikar JN, Yocum AK, et al. The role of 
sarcosine metabolism in prostate cancer progression. Neoplasia. 2013;15(5):491-501. 
412. Huang Y-C, Lee C-M, Chen M, Chung M-Y, Chang Y-H, Huang WJ-S, et al. Haplotypes, loss of 
heterozygosity, and expression levels of glycine N-methyltransferase in prostate cancer. Clin Cancer 
Res. 2007;13(5):1412-20. 
413. Nair R, Roden DL, Teo WS, McFarland A, Junankar S, Ye S, et al. c-Myc and Her2 cooperate to 
drive a stem-like phenotype with poor prognosis in breast cancer. Oncogene. 2014;33(30):3992-4002. 
414. Murphy L, Prencipe M, Gallagher WM, Watson RW. Commercialized biomarkers: new 
horizons in prostate cancer diagnostics. Expert Rev Mol Diagn. 2015;15(4):491-503. 
415. Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, Matusik R, et al. Myc-
driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell. 
2003;4(3):223-38. 
416. Wang F, Flanagan J, Su N, Wang L-C, Bui S, Nielson A, et al. RNAscope: a novel in situ RNA 
analysis platform for formalin-fixed, paraffin-embedded tissues. J Mol Diagn. 2012;14(1):22-9. 
417. Chen L, Mooso BA, Jathal MK, Madhav A, Johnson SD, van Spyk E, et al. Dual EGFR/HER2 
inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3. Clin Cancer 
Res. 2011;17(19):6218-28. 
418. Shiota M, Bishop JL, Takeuchi A, Nip KM, Cordonnier T, Beraldi E, et al. Inhibition of the 
HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in 
castration resistant prostate cancer. Oncotarget. 2015;6(11):9086-98. 
419. Kroon P, Berry PA, Stower MJ, Rodrigues G, Mann VM, Simms M, et al. JAK-STAT blockade 
inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cells. Cancer Res. 
2013;73(16):5288-98. 
  94 
8. Appendix 
List of figures 
Figure 1: Location of the prostate and anatomy 
Figure 2. Mechanism of transcriptional regulation by the androgen receptor  
Figure 3. Current model of prostate cancer progression 
Figure 4. Original Gleason scoring system and recent modifications  
Figure 5: The development of castration resistant prostate cancer  
Figure 6. Molecular hallmarks of prostate cancer and its precursors  
Figure 7. Transcriptional control by the AR in normal and transformed prostate cells 
Figure 8. Interplay of transcription factors, chromatin modifiers and signalling pathways 
Figure 9. The Phosphoinositid-3-kinase signalling pathway 
Figure 10. Transcriptional activation and repression by MYC 
Figure 11. Aims of this study 
 
List of tables 
Table 1. Summary of prostate cancer risk factors 
Table 2: Tumour stage categories 
Table 3: Node stage categories 
Table 4: Metastasis stage categories 
Table 5: Prostate cancer stages defined by TNM, Gleason and PSA 
Table 6: Overview of clinically relevant molecular hallmarks of PCa 
Papers I-V 
